[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 568
1. Ławicki S, Szmitkowski M, Wojtukiewicz M: The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta; 2006 Sep;371(1-2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
  • BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls.
  • Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
  • METHODS: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects.
  • RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group.
  • The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage.
  • We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage.
  • CONCLUSIONS: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631152.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


2. Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, Vollmert C, Illig T, Brauch H: MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat; 2005 Mar;25(3):232-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We isolated constitutional DNA from 274 FFPET samples (229 patients with breast cancer and 45 patients with benign breast diseases) and genotyped 15 polymorphic loci in 10 genes.
  • Furthermore, genotype frequencies matched those observed in a German breast cancer population and other Caucasian populations.
  • [MeSH-minor] Alleles. Breast Diseases / genetics. Breast Diseases / pathology. Breast Neoplasms / genetics. Breast Neoplasms / pathology. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Formaldehyde. Genotype. Humans. Neoplasm Proteins / genetics. Paraffin Embedding. Taq Polymerase

  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15706592.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde; 9007-49-2 / DNA; EC 2.7.7.- / Taq Polymerase
  •  go-up   go-down


3. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


Advertisement
4. Kelly RJ, Barrett C, Swan N, McDermott R: Metastatic phyllodes tumor causing small-bowel obstruction. Clin Breast Cancer; 2009 Aug;9(3):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phyllodes tumor causing small-bowel obstruction.
  • Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0.5%-1.0% of female breast carcinomas.
  • This report highlights a unique case of a metastatic phyllodes breast tumor leading to small bowel obstruction.
  • Phyllodes tumors are generally classified into histologic subtypes of benign, intermediate, and malignant, using agreed classification systems.
  • The tumor characteristics that can lead to the dedifferentiation of a relatively benign phenotype to an overt malignant process are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Ileal Neoplasms / secondary. Intestinal Obstruction / etiology. Phyllodes Tumor / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661046.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Bereznaya NM, Kirnasovskaya EA, Vinnichuk YD, Belova OB, Lukyanova NY: Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. Exp Oncol; 2008 Dec;30(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors.
  • AIM: To study the expression of CD40 by cells of benign and malignant tumors of mammary gland, and to compare the efficacy of lymphocytes antitumor activity against drug resistant and sensitive breast tumors in relevance to CD40 expression.
  • METHODS: Breast tumor explants were cultured with autologous lymphocytes in double diffusion chambers.
  • Expression level of molecules on tumor cells was analyzed using immunohistochemical method (paraffin embedded slides), and on lymphocytes - by the method of indirect immunofluorescence.
  • RESULTS: The highest level of CD40 expression was detected on cells of chemoresistant malignant breast tumors, and the lowest one - on cells of benign breast tumors.
  • The decreased CD40 expression on lymphocytes from patients with drug resistant breast cancer was compared with that on lymphocytes of the patients with drug sensitive breast cancer.
  • The study of antitumor activity of autologous lymphokine activated killer cells (LAK) has shown their pronounced antitumor activity against drug resistant malignant breast tumors.
  • CONCLUSION: Marked antitumor activity of LAK from the patients with drug resistant breast cancer is associated with high expression level of CD40 on tumor cells and with its decreased expression on lymphocytes.
  • [MeSH-major] Antigens, CD40 / biosynthesis. Breast Neoplasms / immunology. Drug Resistance, Neoplasm / immunology. Killer Cells, Lymphokine-Activated / immunology
  • [MeSH-minor] Female. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Intercellular Adhesion Molecule-1 / immunology. Intercellular Adhesion Molecule-1 / metabolism. Lymphocytes / immunology. Lymphocytes / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112427.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antigens, CD40; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


6. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


7. Nielsen BS, Egeblad M, Rank F, Askautrud HA, Pennington CJ, Pedersen TX, Christensen IJ, Edwards DR, Werb Z, Lund LR: Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS One; 2008 Aug 13;3(8):e2959
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression.
  • Matrix metalloproteinase (MMP) 13 (collagenase 3) is an extracellular matrix remodeling enzyme that is induced in myofibroblasts during the earliest invasive stages of human breast carcinoma, suggesting that it is involved in tumor progression.
  • As in human tumors, Mmp13 mRNA was found in myofibroblasts of invasive grade II and III carcinomas, but not in benign grade I and II mammary intraepithelial neoplasias.
  • To determine if MMP13 plays a role in tumor progression, we crossed MMTV-PyMT mice with Mmp13 deficient mice.
  • The absence of MMP13 did not influence tumor growth, vascularization, progression to more advanced tumor stages, or metastasis to the lungs, and the absence of MMP13 was not compensated for by expression of other MMPs or tissue inhibitor of metalloproteinases.
  • We conclude that the expression pattern of Mmp13 mRNA in myofibroblasts of invasive carcinomas in the MMTV-PyMT breast cancer model recapitulates the expression pattern observed in human breast cancer.
  • Our results suggest that MMP13 is a marker of carcinoma-associated myofibroblasts of invasive carcinoma, even though it does not make a major contribution to tumor progression in the MMTV-PyMT breast cancer model.
  • [MeSH-minor] Animals. DNA Primers. Disease Progression. Female. Lung Neoplasms / blood supply. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Mice. Mice, Knockout. Neoplasm Metastasis. Neoplasm Staging. Neovascularization, Pathologic

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17192-7 [15563592.001]
  • [Cites] Nucleic Acids Res. 1991 Aug 11;19(15):4293 [1870982.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1233-40 [15760918.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Circulation. 2005 Oct 25;112(17):2708-15 [16230484.001]
  • [Cites] J Invest Dermatol. 2006 Feb;126(2):486-96 [16374453.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] Int J Exp Pathol. 2006 Oct;87(5):383-91 [16965566.001]
  • [Cites] Dev Biol. 2006 Nov 1;299(1):164-75 [16949567.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):50-9 [17200706.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 23;354(4):846-51 [17275784.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2086-95 [17290405.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):83-97 [17286208.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] PLoS One. 2007;2(11):e1150 [17987127.001]
  • [Cites] Cancer Biol Ther. 2007 Apr;6(4):618-9 [18027438.001]
  • [Cites] Nat Cell Biol. 2007 Dec;9(12):1392-400 [18037882.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):141-52 [18242514.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1378-87 [18316601.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3274-81 [18071307.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):883-7 [10706099.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1997-2003 [11395377.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7091-100 [11585740.001]
  • [Cites] Lab Invest. 2001 Nov;81(11):1485-501 [11706057.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8298-305 [11719463.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3964-76 [12813470.001]
  • [Cites] Aging Cell. 2002 Oct;1(1):57-65 [12882354.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] J Cell Biol. 2003 Sep 15;162(6):1123-33 [12975354.001]
  • [Cites] Cytokine. 2003 Oct;24(1-2):25-35 [14561488.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1887-99 [14578188.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] J Neurosci. 2003 Nov 5;23(31):10107-15 [14602826.001]
  • [Cites] Histochem J. 1979 Jul;11(4):447-55 [91593.001]
  • [Cites] Int J Cancer. 1988 May 15;41(5):707-12 [2835323.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Cell Tissue Res. 1992 Apr;268(1):167-77 [1499048.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Semin Cancer Biol. 1995 Jun;6(3):165-73 [7495985.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1544-50 [8576151.001]
  • [Cites] FEBS Lett. 1996 Feb 12;380(1-2):17-20 [8603731.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17124-31 [8663255.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):453-8 [9531484.001]
  • [Cites] Oncogene. 1998 Jun 18;16(24):3097-104 [9671388.001]
  • [Cites] EMBO J. 1999 Sep 1;18(17):4645-56 [10469644.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Development. 2004 Dec;131(23):5883-95 [15539485.001]
  • [Cites] Histochemistry. 1989;93(1):27-9 [2482274.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • (PMID = 18698413.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA057621; United Kingdom / Medical Research Council / / G0100250; United States / NCI NIH HHS / CA / CA072006; United States / NCI NIH HHS / CA / R01 CA057621; United States / NCI NIH HHS / CA / P01 CA072006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA Primers; EC 3.4.24.- / Matrix Metalloproteinase 13
  • [Other-IDs] NLM/ PMC2493034
  •  go-up   go-down


8. Afify A, Purnell P, Nguyen L: Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol; 2009 Apr;86(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
  • The interaction between the transmembrane receptor CD44 on epithelial tumor cells and its ligand hyaluronan in the surrounding extracellular matrix is important in tumor progression and metastasis.
  • Previously, we demonstrated that hyaluronan (HA) production is increased at tumor-stroma interface in invasive and metastatic human breast cancers when compared with benign or premalignant lesions.
  • We hypothesize that CD44 expression on breast cancer cells is a major contributing factor to cell adhesion, migration and invasion.
  • To evaluate this hypothesis we examined the effects of 3 distinct anti-CD44s and 2 anti-CD44v6 monoclonal antibodies on breast cancer cell lines that expressed high and low CD44s and CD44v6.
  • Our results showed that anti-CD44s could inhibit breast cancer cell adhesion, motility and invasion, while anti-CD44v6 inhibits cell motility.
  • In conclusion, our data suggests that CD44s is involved in breast cancer cell adhesion, motility and invasion through interaction with HA but CD44v6 is involved only in cell motility.
  • Furthermore we concluded that antibodies against different epitopes on CD44 mediate distinct functional effects on breast cancer cells.
  • [MeSH-major] Antigens, CD44 / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Movement
  • [MeSH-minor] Cell Adhesion. Cell Line, Tumor. Cell Membrane / metabolism. Cell Proliferation. Collagen / metabolism. Drug Combinations. Female. Humans. Hyaluronic Acid / metabolism. Laminin / metabolism. Molecular Weight. Neoplasm Invasiveness. Protein Isoforms / metabolism. Proteoglycans / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167378.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Drug Combinations; 0 / Laminin; 0 / Protein Isoforms; 0 / Proteoglycans; 119978-18-6 / matrigel; 9004-61-9 / Hyaluronic Acid; 9007-34-5 / Collagen
  •  go-up   go-down


9. Konukoglu D, Turhan MS, Celik V, Turna H: Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res; 2007 Jun;125(6):747-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
  • Serum VEGF and its relationship between NO and u-PA concentrations are poorly reported in breast cancer patients.
  • The aim of this study was to investigate the relationship between serum levels of VEGF and NO and u-PA in patients with breast cancer.
  • METHODS: Serum concentrations of VEGF, NO and u-PA were measured in groups of pre-operative breast cancer patients without metastasis (n=20), post-operative breast cancer patients without metastasis (four wk after the operation, n=20), breast cancer patients with metastasis (n=23), patients with benign breast disease (n=11) and healthy female controls (n=20).
  • RESULTS: There was no difference in serum concentrations of VEGF, NO and u-PA between controls and patients with benign breast disease.
  • Serum VEGF, NO and u-PA concentrations were significantly higher in pre-operative breast cancer patients than in controls and in patients with benign breast diseases (P<0.01).
  • Post-operative breast cancer patients without metastasis had significantly lower serum VEGF and u-PA concentrations than the pre-operative patients (P<0.01).
  • In breast cancer patients with metastasis, serum VEGF, and u-PA were significantly higher than post-operative nonmetastatic patients (P<0.01).
  • Serum VEGF levels were positively correlated with serum NO levels in breast cancer patients with metastasis (r= 0.386, P<0.05).
  • INTERPRETATION & CONCLUSION: Our results demonstrated that the angiogenic activity was increased in patients with breast cancer.
  • VEGF, NO and uPA seem to be associated with the angiogenetic and metastatic process of breast cancer.
  • [MeSH-major] Biomarkers / metabolism. Breast Neoplasms / blood. Neovascularization, Pathologic. Nitric Oxide / metabolism. Urokinase-Type Plasminogen Activator / metabolism. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Med Res. 2007 Jun;125(6):715-6 [17704546.001]
  • (PMID = 17704550.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A; 31C4KY9ESH / Nitric Oxide; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


10. Aranda C, Sotelo M, Torres A, Zárate M: [Phyllodes tumor and pregnancy. A report of a case]. Ginecol Obstet Mex; 2005 Jul;73(7):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumor and pregnancy. A report of a case].
  • [Transliterated title] Tumor phyllodes y embarazo. Reporte de un caso.
  • Phyllodes tumor is a rare breast fibroepithelial neoplasm of the breast, predominant in females (0.3 to 0.5%).
  • Phyllodes tumor during pregnancy grows fast and its size is relatively big.
  • These tumors can be classified as benign, malignant or neighboring.
  • A 32-year-old patient at 23.4 week of gestation was admitted in the National Institute of Perinatology with a rapidly growing mass in the right breast; diagnosis confirmed by ultrasound study reporting echoic images on right breast, 10 x 10 cm the greatest and 3x3 cm the smallest.
  • A simple mastectomy was performed at the 26.6 week of gestation on the right breast.
  • A possible phyllodes tumour in the right breast was observed during surgery, weight 9.6 pounds, with partial infiltration to major pectoral muscle.
  • Pathology reported a benign phyllodes tumor in the right breast, with surgical borders free of tumor.
  • Phyllodes tumor is rare and can occur during pregnancy.
  • It is unknown if the tumor is hormone-dependent.
  • The growth of a tumor on a subsequent pregnancy is not necessarily associated with recurrency or with a new disorder on the patient, who has had a complete excision.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Female. Humans. Pregnancy


11. Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, Scolyer RA, Lee CS: Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. J Clin Pathol; 2009 Nov;62(11):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 65 PTs (34 benign, 23 borderline and 8 malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Phyllodes Tumor / metabolism. Wnt Proteins / metabolism
  • [MeSH-minor] Cadherins / metabolism. Cohort Studies. Disease Progression. Female. Humans. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Signal Transduction / physiology. Survival Analysis. Tissue Array Analysis / methods. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861560.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP4 protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


12. Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, Hany TF: Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging; 2009 Jun;36(6):919-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten second cancers (18%) were located outside the aerodigestive tract (colon, five; stomach, lymphoma, breast, thymus and kidney, one each).
  • False-positive PET/CT findings were mainly related to benign FDG uptake in the intestine due to benign or precancerous polyps or physiological FDG uptake in other head and neck regions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / diagnostic imaging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1173-8 [14623746.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jun;128(6):703-7 [12049568.001]
  • [Cites] Head Neck. 2002 Apr;24(4):345-9 [11933176.001]
  • [Cites] Neuroradiology. 2008 Nov;50(11):969-79 [18600319.001]
  • [Cites] Radiother Oncol. 2008 May;87(2):221-9 [18410977.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Feb;124(2):208-12 [11226943.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jul;137(1):130-7 [17599580.001]
  • [Cites] Head Neck. 2007 Nov;29(11):986-95 [17563906.001]
  • [Cites] Head Neck. 1989 Sep-Oct;11(5):426-30 [2807882.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1804-10 [15534047.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23 (4):603-8 [10433294.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1343-53 [7882285.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):434-8 [3661848.001]
  • [Cites] Nucl Med Commun. 2005 Aug;26(8):671-87 [16000985.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):275-80 [16266820.001]
  • [Cites] Laryngoscope. 2007 Jul;117(7):1173-9 [17603315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):467-76 [2674075.001]
  • [Cites] Laryngoscope. 2003 May;113(5):888-91 [12792328.001]
  • [Cites] Ann Nucl Med. 2006 Nov;20(9):597-604 [17294670.001]
  • [Cites] Oral Oncol. 2003 Sep;39(6):547-51 [12798396.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Am J Surg. 1964 Oct;108:552-7 [14211447.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1129-32 [15100107.001]
  • (PMID = 19205699.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Schwartz RA, Rothenberg J: Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease. J Cutan Pathol; 2010 Dec;37(12):1251-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease.
  • Metastatic breast cancer of skin may be seen in a number of forms.
  • It is rare to find it in association with a benign melanocytic nevus.
  • We describe a patient with metastatic adenocarcinoma of breast within a benign melanocytic nevus and delineate this occurrence within the context of reviewing cutaneous breast metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 20002237.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


14. Catalano F, Furci M, Fancello R, Costanzo M: Giant recurrent fibromatosis of the breast: a case report. Clinical features and implications for treatment. Chir Ital; 2006 Jul-Aug;58(4):538-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant recurrent fibromatosis of the breast: a case report. Clinical features and implications for treatment.
  • Fibromatosis of the breast is a benign but locally aggressive neoplasm, which has been described under various names including extra-abdominal desmoid tumour and aggressive fibromatosis.
  • It is a rare condition, accounting for approximately 0.2% of all solid tumours of the breast.
  • Clinically and radiologically the lesion mimics breast cancer and the definitive diagnosis is provided by histology.
  • The possible association between breast implants and mammary fibromatosis has been reported.
  • In this study we report a case of giant fibromatosis of the breast observed in a young patient and its extensive recurrence, involving all quadrants of the breast, the pectoralis major muscle, the rectus abdominis muscle sheath and the costal layer.
  • The main clinical and pathological characteristics of this rare disease are illustrated, emphasizing the difficulties encountered both in the diagnosis of the primary lesion and in the management of its giant recurrence, particularly as regards the possibility of obtaining a radical surgical excision and the option of performing breast reconstruction.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / surgery. Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / surgery
  • [MeSH-minor] Adult. Female. Humans. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Pectoralis Muscles / pathology. Pectoralis Muscles / surgery. Rectus Abdominis / pathology. Rectus Abdominis / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999161.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Elmore L, Margenthaler JA: Breast MRI surveillance in women with prior curative-intent therapy for breast cancer. J Surg Res; 2010 Sep;163(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast MRI surveillance in women with prior curative-intent therapy for breast cancer.
  • BACKGROUND: We sought to determine factors that predict the use of breast magnetic resonance imaging (MRI) surveillance in women previously treated for breast cancer and the incidence of in-breast recurrences and/or new cancers identified by MRI.
  • METHODS: We reviewed 141 patients who were treated between 2005 and 2008 who also underwent surveillance breast MRI following their treatment.
  • Patient, tumor, treatment characteristics, and MRI findings were collected.
  • Gail scores were calculated based on the patient's personal and family history prior to the breast cancer diagnosis.
  • One hundred forty-one women underwent 202 surveillance breast MRIs during the study period.
  • Two of the six were invasive breast cancers, while four were benign.
  • Patient age, Gail score, tumor stage, grade, histology, receptor status, and surgical treatment were not predictive of MRI surveillance use.
  • CONCLUSION: Prospective studies are needed to determine which patients may potentially benefit from breast MRI surveillance following curative-intent treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20605594.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. De Cesare A, Fiori E, Burza A, Ciardi A, Bononi M, Izzo L, Volpino P, Cavallaro A, Cangemi V: Malignant fibrous histiocytoma of the breast. Report of two cases and review of the literature. Anticancer Res; 2005 Jan-Feb;25(1B):505-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the breast. Report of two cases and review of the literature.
  • Sarcomas of the breast are uncommon, accounting for less than 1% of all primary malignancies.
  • Two cases of this neoplasm are reported, with histological findings and surgical treatment.
  • The issue of radiation-induced lesions after surgery for carcinoma and the necessity for a correct preoperative diagnosis is examined.
  • A review of the available literature evaluates the histopathological and biological features of MFH of the breast, for which there are no prospective trials, owing to the rarity of this kind of neoplasm.
  • [MeSH-major] Breast Neoplasms / diagnosis. Histiocytoma, Benign Fibrous / diagnosis
  • [MeSH-minor] Adult. Aged. Breast / pathology. Female. Fibroblasts / metabolism. Humans. Immunohistochemistry. Lymphatic Metastasis. Mammography. Time Factors

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816619.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


17. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration biopsy (FNAB) is useful for initial evaluation; nevertheless, malignancy is uncertain when follicular neoplasm is reported.
  • METHODS: We analyzed the clinical files of consecutive patients with cytological diagnoses of follicular neoplasm.
  • Definitive report showed 45 benign (60%) and 30 malignant (40%) cases.
  • Benign cases included 29 goiters, 11 follicular adenomas, and 5 cases of thyroiditis.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • Tumor size of benign lesions was 3.43 ± 2.04 cm, and 4.67 ± 2.78 (p = 0.049) for malignant lesions.
  • Age was 46.95 ± 15.39 years for benign lesions and 48.67 ± 17.28 for malignant lesions (p = 0.66).
  • [MeSH-major] Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


18. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • METHODS: Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the tumours.
  • Constructs overexpressing an AD1-containing isoform (TNC-14/AD1/16) were transiently transfected into breast carcinoma cell lines (MCF-7, T-47 D, ZR-75-1, MDA-MB-231 and GI-101) to assess the effect in vitro on invasion and growth.
  • RESULTS: Quantitative RT-PCR detected AD1 and AD2 mRNA expression in 34.9% and 23.1% of 134 invasive breast carcinomas, respectively.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • CONCLUSIONS: Together these data suggest a highly significant association between AD-containing TNC isoforms and breast cancers in younger women (age ≤40 years), which may have important functional significance in vivo.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


19. Badar F, Moid I, Waheed F, Zaidi A, Naqvi B, Yunus S: Variables associated with recurrence in breast cancer patients-the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev; 2005 Jan-Mar;6(1):54-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variables associated with recurrence in breast cancer patients-the Shaukat Khanum Memorial experience.
  • From a cohort of female breast cancer patients registered at the Shaukat Khanum Memorial Cancer Hospital and Research Center, in Lahore, Pakistan, during the time period extending from December 1994 to December 2002, 700 subjects who were followed up in time, were selected.
  • Those who presented with benign tumors, carcinoma in situ, or metastases were excluded from the analyses.
  • Age, tumor size, nodal status, menopause, estrogen receptor (ER), and progesterone receptor (PR) status, at the time of presentation, were determined.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Follow-Up Studies. Humans. Logistic Models. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pakistan / epidemiology. Registries. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780033.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


20. Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, Xie Y, Zhang J, Chen Y, Budman DR, Shi YE: Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer; 2007 Sep 15;121(6):1296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
  • Synuclein gamma (SNCG), previously identified as a breast cancer-specific gene (BCSG1), is highly expressed in breast carcinomas but not in normal epithelium.
  • SNCG regulates many pathways in growth and progression of breast cancer.
  • To determine if SNCG is a biomarker for clinical prognosis of breast cancer, we generated a panel of murine monoclonal antibodies (mAbs) against human SNCG and correlated SNCG protein expression in 358 clinical breast cancer specimens with clinical outcome.
  • SNCG protein expression was determined in 438 clinical breast specimens by immunohistochemical analysis using mAb 5C5.
  • Expression of SNCG was strongly correlated with the stage, lymph node involvement, metastasis, tumor size and Her-2 status, but its expression was not associated with ER and PR expression status.
  • While 71.4% of advanced breast cancers were positive for SNCG expression, only 26.8% of Stage I/II breast cancers were positive for SNCG expression and 5.2% of benign hyperplasia expressed SNCG.
  • SNCG protein was not detectable in normal tissue adjacent to breast cancer.
  • After a median follow-up of 64 months, patients with an SNCG-positive tumor had a significantly shorter disease-free survival and overall survival and a high probability of death compared no expression of SNCG.
  • SNCG is a new unfavorable prognostic marker for breast cancer progression and a potential target for breast cancer treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. gamma-Synuclein / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal. Blotting, Western. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression. Humans. Immunohistochemistry. Immunoprecipitation. Kaplan-Meier Estimate. Lymphatic Metastasis. Mice. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534899.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / SNCG protein, human; 0 / gamma-Synuclein
  •  go-up   go-down


21. El-Tanani MK, Jin D, Campbell FC, Johnston PG: Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression. Oncogene; 2010 Feb 4;29(5):752-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well.
  • [MeSH-major] Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Membrane Proteins / metabolism. Osteopontin / metabolism. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Animals. Blotting, Northern. Blotting, Western. Cell Adhesion / physiology. Cell Line, Tumor. Cell Movement / physiology. Female. Humans. Immunoprecipitation. Neoplasm Invasiveness / genetics. Promoter Regions, Genetic. RNA, Messenger / analysis. Rats

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901966.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IFITM3 protein, human; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


22. Rohan TE, Li SQ, Hartwick R, Kandel RA: p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev; 2006 Jul;15(7):1316-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study.
  • Disruption of p53 gene function seems to have a pivotal role in carcinogenesis. p53 gene changes occur before the development of breast cancer and therefore might influence breast cancer risk.
  • We investigated the association between p53 protein accumulation and p53 mutations detected in benign breast tissue and risk of subsequent breast cancer.
  • We conducted a case-control study nested within the cohort of 4,888 women in the Canadian National Breast Screening Study who were diagnosed with biopsy-confirmed benign breast disease during active follow-up.
  • Cases were women with benign breast disease who subsequently developed breast cancer; five controls were matched to each case. p53 protein accumulation was assessed immunohistochemically using sections of paraffin-embedded benign breast tissue from 104 cases and 385 controls; for 82 of these cases and 327 of the controls, DNA was successfully extracted from the breast tissue for p53 gene analysis using PCR-single-strand conformation polymorphism/direct sequencing. p53 protein accumulation was associated with a 2-fold increase in risk of progression to breast cancer [adjusted odds ratio (OR), 2.16; 95% confidence interval (95% CI), 1.08-4.30], whereas p53 nucleotide changes overall were not associated with altered risk (adjusted OR, 1.22; 95% CI, 0.68-2.19); those with both p53 immunopositivity and a p53 nucleotide change had an OR (95% CI) of 3.20 (1.21-8.50).
  • The results of this study suggest that p53 protein accumulation and nonpolymorphic intronic changes in p53 are associated with increased risk of progression to breast cancer in women with benign breast disease.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / metabolism. Precancerous Conditions / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Canada / epidemiology. Case-Control Studies. Cohort Studies. DNA Mutational Analysis. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835330.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Singh SS, Velusami SD: Syringomatous adenoma of the nipple: report of a case. Indian J Pathol Microbiol; 2007 Oct;50(4):808-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringomatous adenoma of the nipple is a rarely encountered neoplasm of the breast with histological features similar to eccrine syringoma of the skin.
  • This tumour which is locally invasive with high potential for recurrence if incompletely excised is considered benign and a complete excision is sufficient.
  • We report a case of syringomatous adenoma of the nipple in a postmenopausal diabetic woman who was incidentally found to have a subareolar mass in her right breast.
  • A clinicopathological study and histological differential diagnosis of this unusual tumour is described.
  • [MeSH-major] Nipples / pathology. Syringoma / diagnosis. Syringoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306564.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


24. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • RESULTS: Both groups were found to be homogeneous relative to age, menarche, body mass index, previous gestation, parity, breastfeeding, number of fibroadenomas, family history of breast cancer and tabagism.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Proliferation. Fibroadenoma / pathology. Follicular Phase / metabolism. Ki-67 Antigen / metabolism. Luteal Phase / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Breast Feeding / statistics & numerical data. Female. Humans. Obesity / complications. Progesterone / blood. Tobacco Use Disorder / complications. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


25. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


26. Wauters CA, Sanders-Eras MC, de Kievit-van der Heijden IM, Wesseling P, Venderink DJ, van Dijk Azn R, van den Wildenberg F, Kooistra BW, Strobbe LJ: Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions. Eur J Surg Oncol; 2010 Oct;36(10):957-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified core wash cytology (CWC), an asset in the diagnostic work-up of breast lesions.
  • AIM: A quick and reliable preliminary diagnosis is essential in the management of a same-day breast clinic.
  • METHODS: From April 2008 to April 2009, biopsies were taken from lesions in the breast.
  • CWC was obtained from core needle biopsy (CNB) with a modified technique and classified into the categories: malignant, suspicious for malignancy, atypical, benign and inadequate.
  • RESULTS: CWC was obtained from 226 breast lesions.
  • In 167 of these cases subsequent resection of the lesion was performed revealing 149 carcinomas and 18 benign lesions.
  • Of the 149 malignant cases, 136 were considered as either malignant or suspicious for malignancy by CWC, 7 as atypical, 4 as benign and 2 as inadequate.
  • None of the 18 benign lesions were classified as suspicious or malignant on CWC.
  • CONCLUSIONS: In the vast majority of patients the modified CWC technique can provide a quick and reliable diagnosis of malignant breast lesions.
  • Furthermore, combining CWC with CNB histology can improve adequate, preoperative recognition of the malignant character of breast lesions.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Ambulatory Care / methods. Breast Diseases / diagnosis. Breast Diseases / pathology. Breast Diseases / surgery. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Netherlands. Preoperative Care / methods. Reproducibility of Results. Risk Assessment. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708371.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Harmer V: Breast cancer. Part 3: advanced cancer and psychological implications. Br J Nurs; 2008 Sep 25-Oct 8;17(17):1088, 1090, 1092 passim
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer. Part 3: advanced cancer and psychological implications.
  • This is the last article in this 3-part series on breast cancer.
  • The previous two articles have outlined the principles behind breast awareness and breast health, detailing common benign breast diseases, types of breast cancer and staging, and treatment for breast cancer, including surgery, chemotherapy, radiotherapy and endocrine treatment.
  • The series concludes by giving information on advanced disease, including when a patient presents late with a fungating breast lesion, or if the disease has metastasized from the breast to other organs.
  • Lymphoedema is also described and discussed, and the latter half of this article discusses psychological implications of breast cancer, from diagnosis through the individual treatments.
  • [MeSH-major] Breast Neoplasms / nursing
  • [MeSH-minor] Adaptation, Psychological. Female. Humans. Lymphedema / etiology. Lymphedema / nursing. Neoplasm Metastasis. Palliative Care. Skin Ulcer / etiology. Skin Ulcer / nursing. Social Support

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186363.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


28. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY: Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Müllerian adenosarcoma is a rare neoplasm usually found in postmenopausal women.
  • It is a biphasic tumor, composed of a benign epithelial component and a malignant stromal component.
  • To date, this neoplasm has been reported in only 16 adolescent girls.
  • We present a case of a 10-year-old girl who was diagnosed with müllerian adenosarcoma arising from the endocervix, the youngest female ever reported.
  • On physical examination, her vital signs were stable, and pubertal development was Tanner III breast and Tanner II pubic development.
  • Pathology confirmed a diagnosis of müllerian adenosarcoma originating from the endocervix.
  • After a thorough evaluation of the available literature, review with the Regional Tumor Board and extensive discussions with the family, a decision was made to perform a radical hysterectomy, bilateral salpingectomy, bilateral pelvic lymph node dissection, upper vaginectomy and preservation of ovaries.
  • CONCLUSION: Müllerian adenosarcoma of the endocervix is a very rare pediatric tumor.
  • Due to the rarity of this tumor in this age group, optimal therapy is uncertain.
  • [MeSH-minor] Child. Female. Humans


29. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD: Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer; 2006 Sep 15;119(6):1403-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.
  • Matrix metalloproteinase (MMP) 2 and 9 are involved in cancer invasion and metastasis, and increased levels occur in serum and plasma of breast cancer (BC) patients.
  • In our study, we measured concentration and activity of MMP2/9 in sera of 345 donors classified as low risk (Gail score <1.7), high risk (HR) (Gail score > or =1.7), benign disease or BC.
  • Kruskal-Wallis and Mann-Whitney nonparametric tests showed that total-MMP2 concentration is higher in HR compared to control (p = 0.012), benign (p = 0.001) and cancer (p = 0.007).
  • Active MMP2 (aMMP2) concentration is higher in control than benign and cancer (p < 0.001, respectively).
  • Total and aMMP9 concentrations are higher in cancer than benign (p < 0.001, p = 0.002, respectively).
  • Total-MMP2 and total-MMP9 activities are lower in control than benign (p < 0.001, p = 0.002, respectively) and cancer (p < 0.001, respectively).
  • Total-MMP2 and MMP9 activities are also higher in cancer than benign (p = 0.004, p < 0.001) and HR (p = 0.008, p = 0.007, respectively).
  • Our study provides evidence supporting the potential role of serum MMP2/9 as biomarkers for breast disease classification.
  • [MeSH-major] Breast Diseases / enzymology. Breast Neoplasms / enzymology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Breast / enzymology. Carcinoma, Intraductal, Noninfiltrating / enzymology. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Jul 1;121(1):216-8; author reply 219-23 [17315186.001]
  • (PMID = 16615109.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


30. Craig S, Bui-Mansfield LT, Lusk JD: Radiology pathology conference of Brooke Army Medical Center: trichoblastoma of breast. Clin Imaging; 2009 Jul-Aug;33(4):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology pathology conference of Brooke Army Medical Center: trichoblastoma of breast.
  • The differential diagnosis of a superficial breast lesion detected on mammography typically includes seborrheic keratosis, dermal nevus, epidermal inclusion cyst, and basal cell carcinoma with subcutaneous invasion [Kopans DB.
  • Breast Imaging. 3rd ed.
  • The case presented is of a trichoblastoma of the superficial breast.
  • Trichoblastoma is a benign skin neoplasm that is rarely found in the breast.
  • This case describes and correlates the findings of trichoblastoma of the breast on mammography, sonography, and histology.
  • [MeSH-major] Breast Neoplasms / diagnosis. Mammography / methods
  • [MeSH-minor] Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559355.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Wishart GC, Campisi M, Boswell M, Chapman D, Shackleton V, Iddles S, Hallett A, Britton PD: The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. Eur J Surg Oncol; 2010 Jun;36(6):535-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy.
  • BACKGROUND: Mammography has a lower sensitivity for breast cancer detection in younger women and those with dense breasts.
  • Recent improvements in digital infrared breast imaging suggest there may be a role for this technology and we have studied its performance in 100 women prior to breast needle core biopsy (CB).
  • METHODS: All patients were imaged using a digital infrared breast (DIB) scan (Sentinel BreastScan) prior to breast biopsy.
  • RESULTS: Of 106 biopsies performed in 100 women, 65 were malignant and 41 were benign.
  • CONCLUSION: DIB using NoTouch is an effective adjunctive test for breast cancer detection in women under 70 and appears to be particularly effective in women under 50 where maximal sensitivity (78%) and specificity (75%) were observed.
  • [MeSH-major] Breast Neoplasms / pathology. Thermography / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Humans. Infrared Rays. Middle Aged. Neoplasm Staging. Neural Networks (Computer). Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2010 Sep;7(9):483 [20824903.001]
  • (PMID = 20452740.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Fu Q, Yao GY, Tang XL, Chen LR, Zheng ZX: [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions]. Zhonghua Zhong Liu Za Zhi; 2007 Jan;29(1):34-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions].
  • OBJECTIVE: To investigate the incidence and clinicopathologic significance of MSI and LOH on 3P in breast carcinoma and its precancerous lesions, intraductal papillary adenoma and ductal carcinoma in situ.
  • METHODS: 41 paired sporadic invasive breast carcinomas, 13 archival precancerous lesion specimens of the breast and 14 couples of benign hyperplasia were collected.
  • There was no MSI in benign hyperplasia.
  • Of the 11 loci examined, D3S1295, D3S1029 and D3S1038 were identified as the locus with most frequent LOH which were all correlated significantly with some clinicopathological parameters such as histological type, lymph node metastasis in breast cancer, while D3S1295 and D3S1029 were the most frequent markers in precancerous lesions.
  • Positive expression of hMLH1 and hMSH2 protein was detected in breast carcinomas in scattered distribution and their positive rate was 45% and 40% , respectively.
  • CONCLUSION: Defective expression of MMR genes is closely associated with the development of breast cancer.
  • MSI indicates poor histological differentiation in breast carcinoma.
  • D3S1766 and D2S2739 might be the sensitive sites to detect MSI in breast carcinoma and precancerous lesions.
  • The smallest common LOH deletion regions seem likely to be situated between 3p14 and 3p25, indicating the existence of breast tumor related genes in those regions and some of them might affect tumor development.
  • [MeSH-major] Breast Neoplasms / pathology. Chromosome Deletion. Chromosomes, Human, Pair 3 / genetics. Microsatellite Instability. Precancerous Conditions / pathology
  • [MeSH-minor] Acid Anhydride Hydrolases / metabolism. Adaptor Proteins, Signal Transducing / metabolism. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. DNA Mismatch Repair. Female. Humans. Hyperplasia. Immunohistochemistry. Loss of Heterozygosity. Lymphatic Metastasis. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Staging. Nuclear Proteins / metabolism. Polymerase Chain Reaction. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575691.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


33. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6862-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
  • EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with tumors and 43 patients with benign diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms' tumor 1 susceptibility gene.
  • Moreover, CEA and mammaglobin were specifically expressed in epithelial malignancies, and mammaglobin was mainly expressed in effusions from breast carcinoma (97.3% of specificity).
  • CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions.
  • RT-PCR analysis of CEA, Ep-CAM, and mammaglobin in serous effusions could be a beneficial adjunct to cytology for the diagnosis of malignancy.
  • [MeSH-major] Biomarkers, Tumor. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Antigens / biosynthesis. Antigens, Neoplasm / biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line, Tumor. DNA Primers / chemistry. Female. Genes, Wilms Tumor. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis. Neoplasm Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


34. Filipovski V, Banev S, Janevska V, Dukova B: Granular cell tumor of the breast: a case report and review of literature. Cases J; 2009;2:8551
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the breast: a case report and review of literature.
  • A 22-year-old female patient presented with a breast mass lesion with a clinical suspicion of a fibroadenoma.
  • Histological evaluation revealed a rare benign neoplasm - granular cell tumor.Granular cell tumor is rare neoplasm that may arise in virtually any body site, and in 5% it occurs in the breast.
  • The histogenesis of this tumor is still rather controversial and currently the most acceptable theory is a Schwann cell origin.
  • The main histological feature is granular cytoplasm of the tumor cells.From a clinical point of view there is a similarity between granular cell tumor and mammary carcinoma on mammography and ultrasound.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1992 Feb;116(2):206-8 [1733419.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;403(4):391-400 [6330972.001]
  • [Cites] Eur J Radiol. 1994 Nov;19(1):56-9 [7859762.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):709-11 [10782152.001]
  • [Cites] Cancer. 1953 Jul;6(4):786-9 [13059774.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 2):898-900 [2539575.001]
  • [Cites] Am J Clin Pathol. 1949 Jun;19(6):522-35 [18150636.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] South Med J. 1995 Nov;88(11):1146-8 [7481988.001]
  • [Cites] Diagn Cytopathol. 1996 Dec;15(5):403-8 [8989543.001]
  • [Cites] South Med J. 1997 Nov;90(11):1149-51 [9386062.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):333-4 [12214737.001]
  • [Cites] AMA Arch Pathol. 1955 Dec;60(6):663-8 [13268207.001]
  • [Cites] Arch Pathol Lab Med. 1988 Mar;112(3):302-3 [2830865.001]
  • (PMID = 19918386.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769456
  •  go-up   go-down


35. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ: Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol; 2005 Nov;24(11):766-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells.
  • There is increased staining of endothelins (ET-1, -2, and -3) and receptors (ET-RA and -RB) in invasive breast tumors compared to nonneoplastic tissue, and ETs stimulate MCF-7 cell invasion in vitro.
  • We analyzed ETstimulation of benign and transformed mammary epithelial cells, and whether expression of ETs is sufficient to induce invasiveness.
  • In breast cancer patient serum, ET-1 was increased in those patients with lymph node metastases compared to those with no lymph node involvement; ETs, however, had no mitogenic effect on breast tumor cell lines in vitro.
  • The benign mammary epithelial cell line, hTERT-HME1, and the poorly invasive breast tumor cell line MCF-7 secreted low levels of ET-1, while the invasive cell lines SKBR3 and MDAMB231 secreted high levels.
  • In contrast to transformed cells, ET stimulation or overexpression did not induce an invasive phenotype in benign cells.
  • Benign cells do not respond to ETs, and ET expression is not sufficient to induce invasion; however, the level of ET production by tumor cells correlates with their invasiveness, and increasing expression of the ET axis promotes breast tumor cell invasion via both receptors, while MMP-14 is induced via ET-RA.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelins / biosynthesis. Epithelial Cells / metabolism. Receptor, Endothelin A / biosynthesis. Receptor, Endothelin B / biosynthesis
  • [MeSH-minor] Calcium / metabolism. Cell Line. Cell Line, Tumor. Endothelin-1 / blood. Endothelin-1 / metabolism. Enzyme Induction. Female. Humans. Lymphatic Metastasis. Mammary Glands, Human / metabolism. Mammary Glands, Human / pathology. Matrix Metalloproteinases / biosynthesis. Neoplasm Invasiveness. Phenotype. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274297.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Endothelins; 0 / Receptor, Endothelin A; 0 / Receptor, Endothelin B; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


36. Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, Toropygin IY, Vlasova MA, Safarova MR, Makarov OV, Archakov AI: Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochemistry (Mosc); 2006 Apr;71(4):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions.
  • The thermostable fraction of serum samples from patients with ovarian, uterus, and breast cancers and benign ovarian tumor was analyzed using two-dimensional electrophoresis combined with MALDI-TOF(-TOF)-mass spectrometry.
  • Of them, alpha-1-acid glycoprotein and clusterin are expressly down-regulated in breast cancer, whereas transthyretin is decreased specifically in ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Electrophoresis, Gel, Two-Dimensional / methods. Neoplasm Proteins / blood. Proteome / analysis. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / blood. Breast Neoplasms / metabolism. Female. Humans. Middle Aged. Ovarian Neoplasms / blood. Ovarian Neoplasms / metabolism. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Uterine Neoplasms / blood. Uterine Neoplasms / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615854.001).
  • [ISSN] 0006-2979
  • [Journal-full-title] Biochemistry. Biokhimii︠a︡
  • [ISO-abbreviation] Biochemistry Mosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


37. Tan EY, Tan PH, Yong WS, Wong HB, Ho GH, Yeo AW, Wong CY: Recurrent phyllodes tumours of the breast: pathological features and clinical implications. ANZ J Surg; 2006 Jun;76(6):476-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent phyllodes tumours of the breast: pathological features and clinical implications.
  • BACKGROUND: Phyllodes tumours (PT) of the breast are fibro-epithelial neoplasms that are known to recur locally in up to 19% of patients.
  • It is still debatable as to whether it is necessary to subject the patient to repeat surgery to obtain pathologically negative margins after a diagnosis of a benign or borderline PT is made.
  • Data, including age at the time of diagnosis, clinical presentation, histological features, type of surgery carried out, clinical progression and characteristics of locally recurrent disease, were analysed.
  • Comparisons were made between those with benign, borderline and malignant tumours, as well as between those who developed a malignant recurrence and those who did not.
  • RESULTS: The mean age at the time of diagnosis was 39.6 +/- 7.4 years and the mean tumour size was 6.0 +/- 5.1 cm.
  • A total of 22 patients were classified as having benign tumour, 9 as having borderline tumour and 6 as having malignant tumour.
  • The majority of recurrent tumours were histologically similar to the initial tumour; however, seven patients (19%) developed a malignant recurrence from an initially benign or borderline tumour.
  • CONCLUSIONS: It may be acceptable to use an expectant management towards benign and borderline tumours that are excised without adequate surgical margins.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged. Reoperation. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] ANZ J Surg. 2006 Oct;76(10):956. Hoon, Tan Puay [corrected to Tan, Puay Hoon]; Hui, Ho G [corrected to Ho, Gay Hui]
  • (PMID = 16768772.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


38. Sanders ME, Page DL, Simpson JF, Schuyler PA, Dale Plummer W, Dupont WD: Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer; 2006 Apr 1;106(7):1453-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.
  • BACKGROUND: Radial scars (RS) are benign breast lesions that have been implicated as independent risk factors for invasive breast carcinoma (IBC).
  • METHODS: A retrospective cohort study of 9556 women who underwent biopsy between 1950-1986 and enrolled in the Nashville Breast Cohort was performed to investigate the association between RS in a benign breast biopsy and the risk of IBC.
  • Although the presence of RS in a benign breast biopsy mildly elevates the risk of IBC risk, the current analysis indicated that this risk can be largely attributed to the category of coexistent PD.
  • [MeSH-major] Breast / pathology. Breast Diseases / complications. Breast Neoplasms / etiology. Carcinoma / etiology
  • [MeSH-minor] Adult. Aged. Biopsy. Case-Control Studies. Female. Humans. Hyperplasia / complications. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16502407.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA68485; United States / NCI NIH HHS / CA / P50-CA098131; United States / NCI NIH HHS / CA / R01-CA50468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Gashi-Luci LH, Limani RA, Kurshumliu FI: Invasive ductal carcinoma within fibroadenoma: a case report. Cases J; 2009;2:174
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Fibroadenoma is the most common benign tumor of the female breast with the highest incidence before age 30.
  • CASE PRESENTATION: We present a rare case of a 39 years old female with invasive ductal carcinoma arising within fibroadenoma.
  • CONCLUSION: There is a low percentage of fibroadenomas harboring carcinoma; however, all breast lumps should be seriously managed; extirpation and histological examination is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):244-6 [19574682.001]
  • [Cites] Pathol Int. 1994 Dec;44(12):874-7 [7866572.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Am J Clin Pathol. 1991 May;95(5):614-22 [1850948.001]
  • [Cites] Surg Gynecol Obstet. 1985 Feb;160(2):99-104 [2982218.001]
  • [Cites] Can J Surg. 1985 Jul;28(4):372-4 [2990650.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):736-42 [11345838.001]
  • [Cites] Major Probl Pathol. 1979;11:i-xvi, 1-466 [547120.001]
  • [Cites] Cancer. 1975 Feb;35(2):450-6 [1111920.001]
  • [Cites] Int J Clin Oncol. 2004 Aug;9(4):334-8 [15375712.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):572-4 [15297206.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):795-7 [12354814.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):590-4 [6329129.001]
  • (PMID = 19946485.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783130
  •  go-up   go-down


40. Siegmann KC, Baur A, Vogel U, Kraemer B, Hahn M, Claussen CD: Risk-benefit analysis of preoperative breast MRI in patients with primary breast cancer. Clin Radiol; 2009 Apr;64(4):403-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-benefit analysis of preoperative breast MRI in patients with primary breast cancer.
  • AIM: To analyse and compare the risks and benefits of preoperative breast MRI (BMRI) in patients with primary breast cancer (PBC), and to determine the influence of mammographic breast density (BD) and histological tumour type (TT).
  • MATERIALS AND METHODS: One hundred and nineteen patients who underwent preoperative bilateral breast MRI for staging of PBC during a 1-year period from July 2005 to August 2006 were prospectively evaluated.
  • Biopsies of benign MRI detected lesions were defined as disadvantageous.
  • Seventeen women underwent mastectomy instead of breast conservation, eight patients underwent extended excision, 21 additional lesions were clarified by MRI intervention, and two ultrasound-detected lesions were not biopsied because of negative MRI.
  • Twelve patients (10.1%) had additional biopsies of MRI-detected benign lesions, and therefore, had an unfavourable outcome due to BMRI.
  • The percentage of additional biopsies of benign lesions (10.1%) seems acceptable.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Preoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / ultrasonography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / ultrasonography. Female. Humans. Magnetic Resonance Imaging / methods. Mammography. Middle Aged. Needs Assessment. Neoplasm Staging. Prospective Studies. Risk Assessment. Treatment Outcome. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264186.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


41. Jordan SJ, Green AC, Whiteman DC, Webb PM, Australian Ovarian Cancer Study Group: Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol; 2007 Nov;107(2):223-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
  • OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer.
  • Such a sequence would predict some shared risk factors between the different tumor types.
  • To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors.
  • Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires.
  • RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types.
  • Hormonal contraceptives and breast-feeding were unrelated to risk.
  • However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking.
  • Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer.
  • [MeSH-minor] Adult. Aged. Australia. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Female. Health Status. Humans. Life Style. Middle Aged. Neoplasm Invasiveness. Odds Ratio. Reproductive History. Risk Assessment. Risk Factors. Smoking / adverse effects. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662378.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


42. Gast MC, van Dulken EJ, van Loenen TK, Kingma-Vegter F, Westerga J, Flohil CC, Knol JC, Jimenez CR, van Gils CH, Wessels LF, Schellens JH, Beijnen JH: Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling. Int J Biol Markers; 2009 Jul-Sep;24(3):130-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.
  • AIM: Novel diagnostic breast cancer markers have been extensively searched for in the proteome, using, among others, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).
  • MATERIAL AND METHODS: We investigated breast cancer (n=75) and control (n=26) serum and tissue samples, collected prospectively by rigorous adherence to a strictly defined protocol.
  • RESULTS: Three serum peaks were significantly associated with breast cancer, while in tissue, 27 discriminative peaks were detected.
  • Several peak clusters gradually increased or decreased in intensity from healthy to benign to cancer, or with increasing cancer stage.
  • These are likely to have been generated by (breast) cancer-specific proteolytic activity in the tumor microenvironment.
  • CONCLUSIONS: These albumin fragment scan potentially provide insights into the pathophysiological mechanisms associated with, or underlying, breast cancer, and aid in improving breast cancer diagnosis.
  • [MeSH-major] Blood Proteins / analysis. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Aged. Diagnosis-Related Groups. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787623.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


43. Kärjä V, Alafuzoff I: Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy. Clin Neuropathol; 2006 Jan-Feb;25(1):37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein p62 common in invaginations in benign meningiomas--a possible predictor of malignancy.
  • Expression of p62 has been seen in inclusions in neoplasias like hepatocellular and breast carcinomas but also in neuronal inclusions of degenerative brain disorders.
  • MATERIAL: The study material included 45 benign meningiomas of postmenopausal women operated in Kuopio University Hospital between 1994 and 2002.
  • CONCLUSION: Our results indicate that in the benign not recurrent meningiomas, signs of functioning proteosomal system, can be detected using the p62 labeling.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Biomarkers, Tumor / analysis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Brain / metabolism. Brain / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Postmenopause

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465773.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / SQSTM1 protein, human
  •  go-up   go-down


44. Neagu A, Muscă S, Slătineanu S, Pricop M: [Breast conservative surgery]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast conservative surgery].
  • Breast conservative therapy is considered an adequate therapeutical method for early stage breast cancer.
  • Breast conservative treatment consists of partial mastectomy, axillary dissection and radiotherapy.
  • The frozen sections examination provides prompt differentiation between benign/malign lesions and precise assessment of the oncologic margins of the specimen.
  • Preoperative marking of nonpalpable breast lesion with hook wire represents a progress for breast conservative treatment.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental / methods
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607830.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 18
  •  go-up   go-down


45. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL: Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat; 2006 Jun;97(3):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
  • Phyllodes tumors of the breast are biphasic stromal and epithelial tumors histologically similar to benign fibroadenomas, but with a neoplastic stromal component.
  • In a single case of phyllodes tumor containing a malignant epithelial component the malignant epithelium and stroma partially share an LOH genotype, suggesting a common precursor cell for the biphasic malignant components.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Loss of Heterozygosity. Neoplasms, Multiple Primary / genetics. Neoplasms, Second Primary / genetics. Oligonucleotide Array Sequence Analysis. Phyllodes Tumor / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Epithelial Cells / pathology. Female. Gene Expression Profiling. Genome, Human. Humans. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791486.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / NCI P50 CA89393-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


46. Rippy L, Marsden J: Is HRT justified for symptom management in women at higher risk of developing breast cancer? Climacteric; 2006 Dec;9(6):404-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is HRT justified for symptom management in women at higher risk of developing breast cancer?
  • Prescriptions for HRT have fallen over the last 3 years due to anxiety provoked about breast cancer risk and recurrence that has been generated by recent clinical trials.
  • In women at population risk of breast cancer, these trials have not shown risks greater than estimates from clinical trial evidence that predated them.
  • For women at increased breast cancer risk due to a family history or high-risk benign breast conditions, clinical trial data are limited but suggest a lack of an additive effect of HRT on risk.
  • In symptomatic breast cancer survivors, observational data suggest no increase in recurrence but these data are open to bias.
  • The randomized LIBERATE trial evaluating tibolone in breast cancer survivors is fully recruited and continuing.
  • The current clinical climate is 'HRT adverse' but, due to a lack of effective alternatives for symptom relief, women at higher breast cancer risk and breast cancer survivors are still requesting information about HRT.
  • [MeSH-major] Breast Neoplasms / chemically induced. Estrogen Replacement Therapy
  • [MeSH-minor] Aged. Female. Genetic Predisposition to Disease. Humans. Middle Aged. Neoplasm Recurrence, Local / chemically induced. Patient Education as Topic. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085372.001).
  • [ISSN] 1369-7137
  • [Journal-full-title] Climacteric : the journal of the International Menopause Society
  • [ISO-abbreviation] Climacteric
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


47. Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM: Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging; 2007 Jan;25(1):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging.
  • PURPOSE: To determine whether combining 3D fast imaging employing steady-state acquisition (FIESTA) and T1-weighted contrast-enhanced (CE) sequences could help characterize lesions in 32 women with benign, in situ, or invasive breast lesions.
  • Since FIESTA provides both T1 and T2 information on the same three-dimensional (3D) matrix as high-resolution T1-weighted dynamic data, we aimed to verify whether invasive lesions could be separated from in situ and/or benign lesions using quantitative FIESTA measures of tissue intensity and homogeneity.
  • RESULTS: On FIESTA most invasive cancer lesions were hypointense compared to surrounding normal tissue (mean lesion intensity was 89% of normal tissue intensity), whereas most ductal and benign lesions appeared hyperintense compared to surrounding normal tissue (lesions at 100.9% and 121.9% of normal tissue intensity, respectively).
  • Measures obtained from resampled T2-weighted data showed no significant differences between the invasive and benign lesion groups.
  • [MeSH-major] Breast Neoplasms / diagnosis. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173311.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069587; United States / NCI NIH HHS / CA / R01 CA116182
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


48. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ: A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1152-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of relative telomere length and postmenopausal breast cancer risk.
  • During breast cancer progression, a substantial increase in chromosomal aberrations is observed in the transition from ductal hyperplasia to carcinoma in situ.
  • Consequently, telomere dysfunction, which leads to genomic instability, is hypothesized to play a causal role in the progression of breast cancer.
  • However, the few epidemiologic studies that have assessed the relationship between telomere length and breast cancer risk have been inconsistent.
  • We used quantitative real-time PCR to measure relative telomere length in genomic DNA extracted from peripheral blood leukocytes and examined its association with postmenopausal breast cancer risk in 1,122 invasive breast cancer cases and 1,147 matched controls free of diagnosed cancer nested within the prospective Nurses' Health Study.
  • Our data show that relative telomere length was not associated with a significant elevation in postmenopausal breast cancer risk [below versus above median; odds ratio, 1.23; 95% confidence interval, 0.94-1.60; P(trend) = 0.20].
  • Other established breast cancer risk factors such as family history of breast cancer and history of benign breast disease were not associated with relative telomere length in separate linear regression models each adjusted for age and disease status (P > or = 0.07).
  • Our results provide little support for an important role of telomere length, as measured in peripheral blood leukocytes, as a biomarker of breast cancer risk.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 May 15;68(10):3618-23 [18483243.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1696-700 [18000505.001]
  • [Cites] Mech Ageing Dev. 2000 Nov 15;119(3):89-99 [11080530.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e47 [12000852.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 [12928346.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):984-8 [15300252.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2900-6 [3986816.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10114-8 [1438199.001]
  • [Cites] Curr Opin Oncol. 1996 Jan;8(1):66-71 [8868103.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 [9731736.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):157-67 [10432279.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1263-71 [15746160.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1823-30 [16567770.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:531-57 [16824017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 [17416776.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5538-44 [17545637.001]
  • [Cites] Aging Cell. 2007 Dec;6(6):769-74 [17925004.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5917-21 [10606235.001]
  • (PMID = 19293310.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082838; United States / NCI NIH HHS / CA / CA065725; United States / NCI NIH HHS / CA / R01 CA049449-19; United States / NCI NIH HHS / CA / R01 CA065725-05; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / T32 CA009001-33; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / CA132190-02; United States / NCI NIH HHS / CA / CA49449; United States / NCI NIH HHS / CA / CA009001-33; United States / NCI NIH HHS / CA / R01 CA065725; United States / NCI NIH HHS / CA / R01 CA082838; United States / NCI NIH HHS / CA / R03 CA132190-02; United States / NCI NIH HHS / CA / T32 CA09001; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / CA132190; United States / NCI NIH HHS / CA / R03 CA132190; United States / NCI NIH HHS / CA / T32 CA009001; United States / NCI NIH HHS / CA / CA065725-05; United States / NCI NIH HHS / CA / R01 CA049449; United States / NCI NIH HHS / CA / U01 CA049449; United States / NCI NIH HHS / CA / R01 CA082838-09
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 2DI9HA706A / Estrone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ NIHMS102391; NLM/ PMC2732000
  •  go-up   go-down


49. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesothelioma (MM) is a locally aggressive and highly lethal tumor of serosal cavities that is rarely associated with clinically detectable metastasis to distant organs.
  • Effusions from patients diagnosed with ovarian (=24) and breast (=38) adenocarcinomas and MM (=24) (total = 86) were analyzed for 67-kd LR protein expression, using immunocytochemistry.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Nine benign effusions that were additionally studied for protein expression were uniformly negative, as were all reactive mesothelial cells in malignant effusions.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


50. Yen JY, Ko CH, Yen CF, Yang MJ, Wu CY, Juan CH, Hou MF: Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan. Psychiatry Clin Neurosci; 2006 Apr;60(2):147-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life, depression, and stress in breast cancer women outpatients receiving active therapy in Taiwan.
  • The aims of the present study were to compare the quality of life (QoL), depression and stress between patients with malignant breast cancer and those with benign breast tumors.
  • The present study also examined the factors related to QoL among the patients who were receiving active treatment for breast cancer.
  • Among the 97 patients participating in the study, 73 patients were diagnosed as having malignant breast cancer (malignant group) and 24 as having benign tumors (benign group).
  • Quality of life, depression and stress were compared between the malignant and benign groups, and the factors related to QoL were also examined.
  • Depression was significantly associated with QoL for both the malignant and benign groups, and the stress from health problem was the most significant predictors for QoL among the malignant group.
  • The breast cancer patients suffered more severe psychological difficulty under active treatment than did the benign group patients.
  • [MeSH-major] Breast Neoplasms / psychology. Breast Neoplasms / therapy. Depression / etiology. Quality of Life / psychology. Stress, Psychological / etiology
  • [MeSH-minor] Adult. Demography. Family / psychology. Female. Health Status. Humans. Middle Aged. Neoplasm Staging. Psychology. Severity of Illness Index. Surveys and Questionnaires


51. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT: Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol; 2010 Mar;116(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
  • RESULTS: Histopathology showed benign tumors in 25 patients, borderline tumors in 13 patients, and malignant tumors in 95 patients.
  • In distinguishing malignant/borderline from benign ovarian tumors, the accuracy of PET/CT (0.921) was higher than that of pelvis US (0.830) and abdomino-pelvic CT or pelvis MRI (0.749; P=0.013).
  • In addition, PET/CT detected new, unexpected co-existing malignant tumors in five (3.8%) cases including two thyroid tumors, two breast tumors, and one pancreatic neuroendocrine cancer.
  • CONCLUSION: PET/CT is superior to pelvis US, abdomino-pelvic CT, and pelvic MRI for diagnosis of malignant ovarian tumors and is useful in revealing metastatic ovarian cancer and co-existing malignant tumors.
  • [MeSH-major] Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. ROC Curve. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Doppler. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926121.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, Van Laere SJ, Van Marck E, Vermeulen PB, Dirix LY: Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther; 2009 Dec;8(23):2252-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.
  • In this study, a comparative quantitative methylation profiling of inflammatory breast cancer (IBC) and non-IBC was set up for the identification of tumor-specific methylation patterns.
  • Methylation ratios of six genes (DAPK, TWIST, HIN-1, RASSF1A, RARbeta2 and APC) were measured in benign breast tissues (n = 9) and in tumor samples from non-IBC (n = 81) and IBC (n = 19) patients using quantitative methylation-specific PCR.
  • Median methylation ratios observed in breast cancer (n = 100) were significantly higher than those observed in benign breast tissues for five of six genes (TWIST, HIN-1, RASSF1A, RARbeta2 and APC).
  • Using the maximal methylation ratio observed in benign breast tissue as a threshold, the methylation frequency of two genes, RARbeta2 and APC, was significantly increased in IBC (n = 19) when compared to non-IBC (n = 81): 53 vs. 23% for RARbeta2 (p = 0.012) and 84 vs. 54% for APC (p = 0.017).
  • Using hierarchical clustering, methylation patterns could not classify breast cancers according to their phenotype.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast / pathology. Breast Neoplasms / genetics. DNA Methylation. Inflammation / genetics
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. CpG Islands. Cytokines / genetics. Death-Associated Protein Kinases. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Invasiveness. Nuclear Proteins / genetics. Phenotype. Polymerase Chain Reaction. Prognosis. Promoter Regions, Genetic / genetics. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics. Twist Transcription Factor / genetics

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Dec;8(23):2260-2 [19901521.001]
  • (PMID = 19829046.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Nuclear Proteins; 0 / RARB2 protein, human; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / SCGB3A1 protein, human; 0 / TWIST1 protein, human; 0 / Tumor Suppressor Proteins; 0 / Twist Transcription Factor; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


53. Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M: Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors. Pol Arch Med Wewn; 2008 Sep;118(9):464-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
  • The direct production of this cytokine has been reported in tumor cell lines in vitro and in solid tumors in vivo.
  • OBJECTIVES: In the present study, the levels of M-CSF in patients with breast cancer and in those with a benign breast tumor were evaluated.
  • PATIENTS AND METHODS: The study group was made up of 70 patients with breast cancer and 20 patients with benign tumors and the control group of 30 healthy women.
  • RESULTS: Statistically higher levels of M-CSF and CA 15-3 were found in breast cancer patients as compared to the benign tumor and control groups.
  • CONCLUSIONS: The above data suggests that M-CSF might be useful in both diagnostics and differential diagnosis of benign tumors and breast cancer (except for the lowest degree of the clinical progression).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood
  • [MeSH-minor] Adult. Aged. CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846980.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


54. Tan PH, Jayabaskar T, Chuah KL, Lee HY, Tan Y, Hilmy M, Hung H, Selvarajan S, Bay BH: Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol; 2005 Apr;123(4):529-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast: the role of pathologic parameters.
  • We aimed to establish whether morphologic parameters were prognostically important in a large series of breast phyllodes tumors in Asian women.
  • Of 335 phyllodes tumors diagnosed at the Department of Pathology, Singapore General Hospital, Singapore, between January 1992 and December 2002, 250 (74.6%) were benign, 54 (16.1%) borderline, and 31 (9.3%) malignant, based on histologic review of archival slides.
  • The 7 women who died of disease during follow-up had malignant phyllodes tumor at the outset and experienced recurrences, and death was preceded by distant metastases.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Adolescent. Aged. Asia. Female. History, 16th Century. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743740.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Moore A, Hendon A, Hester M, Samayoa L: Secondary angiosarcoma of the breast: can imaging findings aid in the diagnosis? Breast J; 2008 May-Jun;14(3):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary angiosarcoma of the breast: can imaging findings aid in the diagnosis?
  • Secondary angiosarcomas, although rare, are aggressive tumors that can develop in breast tissue that has undergone prior radiation therapy.
  • We present three cases of secondary angiosarcoma of the breast in the setting of prior breast irradiation.
  • Imaging findings include cutaneous nodules and progressive skin or trabecular thickening in an area of the breast separate from the patient's original breast carcinoma.
  • These imaging findings may enable the radiologist to suggest this diagnosis, even when the clinical presentation is more benign.
  • [MeSH-major] Breast Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Radiation-Induced / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Fatal Outcome. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476885.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Ko E, Han W, Lee JW, Cho J, Kim EK, Jung SY, Kang MJ, Moon WK, Park IA, Kim SW, Kim KS, Lee ES, Min KH, Kim SW, Noh DY: Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Res Treat; 2008 Nov;112(1):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to determine factors that predict under-evaluation of malignancy in patients diagnosed with atypical ductal hyperplasia (ADH) at ultrasound-guided core needle biopsy (CNB), and to develop a prediction algorithm for scoring the possibility of a diagnosis upgrade to malignancy based on clinical, radiological and pathological factors.
  • This system was able to identify a subset of patients with lesions likely to be benign, indicating that imaging follow-up rather than surgical excision may be appropriate.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Diagnostic Imaging. Hyperplasia / pathology. Hyperplasia / ultrasonography
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Female. Humans. Mammography. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060577.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Sampatanukul P, Boonjunwetwat D, Thanakit V, Pak-Art P: Integrated criteria of fine-needle aspiration cytology and radiological imaging for verification of breast cancer in nonpalpable lesions. J Med Assoc Thai; 2006 Feb;89(2):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated criteria of fine-needle aspiration cytology and radiological imaging for verification of breast cancer in nonpalpable lesions.
  • OBJECTIVES: To evaluate the accuracy of using radiologic, cytologic and integrated radiologic and cytologic criteria in diagnosis of nonpalpable breast lesions.
  • MATERIAL AND METHOD: From January 2003 to May 2004, a prospective study of performing fine-needle aspiration biopsy (FNAB) was carried out at King Chulalongkorn Memorial Hospital on female patients with nonpalpable or vaguely palpable lumps that needed ultrasound localization for the direction and depth.
  • RESULTS: There were 162 lesions from 150 patients, consisting of 29 malignant neoplasms (17.9%) and 133 benign lesions (82.1%).
  • Two others had falsely negative cytologic diagnosis.
  • CONCLUSION: The integrated criteria provide the most accuracy rate and sensitivity rate for detection of malignancy in nonpalpable breast lesions.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiography. Carcinoma / pathology. Carcinoma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Mammography / methods. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579012.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


58. Papachristopoulou G, Avgeris M, Scorilas A: Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost; 2009 Feb;101(2):381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and study of KLK4 in benign and malignant breast tumours.
  • The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours.
  • Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens.
  • Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients.
  • ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Kallikreins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Cell Line, Tumor. Female. Humans. Logistic Models. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Prognosis. RNA, Messenger / analysis. ROC Curve. Receptors, Progesterone / analysis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190825.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Progesterone; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


59. Drukier AK, Ossetrova N, Schors E, Krasik G, Grigoriev I, Koenig C, Sulkowski M, Holcman J, Brown LR, Tomaszewski JE, Schnall MD, Sainsbury R, Lokshin AE, Godovac-Zimmermann J: High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics. J Proteome Res; 2006 Aug;5(8):1906-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics.
  • Sensitivity and specificity of about 95% have been achieved for blood-based detection of breast cancer in pilot studies on 250 patients and 95 controls.
  • Pilot studies indicate that this methodology may also allow differentiation of malignant breast cancer from benign lesions and can provide similar sensitivity and specificity for other epithelial cancers such as prostate cancer, ovarian cancer and melanoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood. Breast Neoplasms. Neoplasm Proteins / analysis. Photons. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoassay / methods. Interleukin-6 / blood. Interleukin-8 / blood. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity. Statistics as Topic. Tumor Necrosis Factor-alpha / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889412.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


60. Sakurai K, Enomoto K, Amano S: [Long-term results of surgical therapy for phyllodes tumor of the breast]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2784-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of surgical therapy for phyllodes tumor of the breast].
  • We report that the long-term results of surgical therapy for phyllodes tumor of the breast.
  • During ten years, we experienced twenty-eight patients of phyllodes tumors of the breast.
  • The patients with local recurrence were diagnosed the benign phyllodes tumor of the breast at the first operation.
  • If the pathological diagnosis was benign phyllodes tumor and surgical margin was negative at the first operation, it is necessary to follow up the patients, because there is a risk of local and distant metastasis.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Mussari S, Sabino Della Sala W, Busana L, Vanoni V, Eccher C, Zani B, Menegotti L, Tomio L: Full-dose intraoperative radiotherapy with electrons in breast cancer. First report on late toxicity and cosmetic results from a single-institution experience. Strahlenther Onkol; 2006 Oct;182(10):589-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-dose intraoperative radiotherapy with electrons in breast cancer. First report on late toxicity and cosmetic results from a single-institution experience.
  • PURPOSE: To investigate the feasibility of applying exclusive intraoperative radiation therapy (IORT) after conservative surgery in limited-stage breast carcinoma and to evaluate late effects and cosmetic results after this new conservative treatment.
  • PATIENTS AND METHODS: From October 2000 to November 2002, 47 consecutive patients with unifocal breast carcinoma up to a diameter of 2 cm received conservative surgery followed by IORT with electrons as the sole adjuvant local therapy.
  • During follow-up, a radiologic assessment with mammography and sonography was periodically performed and any breast-imaging alterations were reported.
  • RESULTS: After a follow-up ranging from 36 to 63 months (median, 48 months), 15 patients developed breast fibrosis (grade 2 in 14 patients, grade 3 in one patient), two patients presented with grade 3 skin changes, one patient developed a clinically relevant fat necrosis, and one patient showed breast edema and pain.
  • Two patients developed contralateral breast cancer and one distant metastases; no local relapses occurred.
  • In four patients (8%), mammographic and sonographic findings suggested malignant lesions and required a rebiopsy to confirm the benign nature of the lesion.
  • CONCLUSION: IORT in breast carcinoma is still an experimental treatment option for select patients with breast cancer and its application should be restricted to prospective trials.
  • Although preliminary data on local control are encouraging, a longer follow-up is needed to confirm the efficacy of IORT in breast cancer and to exclude that severe late complications compromise the cosmetic results or modify the radiologic breast appearance during follow-up increasing the need for additional investigations.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Electrons / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Radiation Injuries / etiology. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Aged. Feasibility Studies. Female. Humans. Intraoperative Care / methods. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013572.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Kwon S, Kang SH, Ro J, Jeon CH, Park JW, Lee ES: The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer; 2005 Jul 15;104(2):251-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma.
  • BACKGROUND: Circulating occult tumors cells could be used for the surveillance of metastases after primary breast carcinoma therapy, but their detection is limited by the lack of specific molecular markers.
  • To date, however, the use of MAGEs in the detection of occult tumor cells using reverse transcription-polymerase chain reaction (RT-PCR) has been limited because of the heterogeneity and low expression of individual MAGEs in tumor tissues.
  • We assessed the ability of the MMRPs to detect the expression of MAGE-A gene subtypes in peripheral blood obtained from patients with benign or malignant breast disease.
  • RESULTS: MAGE-A gene expression was not detected in 32 patients with benign disease but was detected in 1 of 31 patients (3%) patients with negative lymph node breast carcinoma, in 10 of 52 patients (19%) with 1-3 positive lymph nodes, in 11 of 53 patients (21%) with > or = 4 positive lymph nodes, and in 20 of 52 patients (39%) with metastatic disease.
  • The results also showed that the detection of MAGE-A gene expression in the blood predicted tumor progression or recurrence.
  • CONCLUSIONS: The results suggested that MAGE-A gene expression may be used for the surveillance of circulating breast carcinoma cells after primary therapy by RT-nested PCR using MMRPs.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Neoplasm Proteins / genetics. Neoplastic Cells, Circulating / metabolism
  • [MeSH-minor] Adult. Aged. Carcinoma / genetics. Carcinoma / pathology. Female. Gene Expression. Humans. Lymphatic Metastasis. Melanoma-Specific Antigens. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937912.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


63. Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P, Halon A, Staszek U, Szelachowska J, Pudelko M, Bebenek M, Harlozinska-Szmyrka A, Kornafel J: Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res; 2010 Sep;16(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factors a, C and d in human breast tumors.
  • Available evidence suggests that vascular endothelial growth factor (VEGF) a potent regulator of vasculogenesis and tumor angiogenesis may be a predictor of recurrence in breast cancer patients.
  • We sought to determine whether VEGF serum levels (VEGF-A, VEGF-C and VEGF-D) in 377 patients with malignant and benign breast tumors differ and whether there is association between vascular growth factors, clinicopathologic features and prognosis.
  • In Cox model values of angiogenic serum markers and recognized prognostic markers in breast cancer, VEGF-C turned out as independent prognostic factor.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor D / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / mortality. Neovascularization, Pathologic / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 1;94(11):2855-61 [12115372.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4370-9 [15806151.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):512-7 [16750560.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12):1794-7; discussion 1797-8 [17465468.001]
  • [Cites] Indian J Med Res. 2007 Jun;125(6):747-51 [17704550.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4695-704 [16034044.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):467-83 [15982726.001]
  • [Cites] J Cell Mol Med. 2007 Jan-Feb;11(1):120-8 [17367506.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Scand J Clin Lab Invest. 2002;62(5):343-50 [12387579.001]
  • [Cites] Tumour Biol. 2006;27(6):302-8 [17028465.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):928-33 [15383417.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1217-22 [12973845.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):978-85 [17912242.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):553-61 [15668703.001]
  • [Cites] Angiogenesis. 2003;6(4):283-7 [15166496.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3121-8 [9738584.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):135-43 [15692755.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Sep;24(5):426-30 [10542924.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):159-64 [11437102.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3491-4 [11705867.001]
  • (PMID = 19821158.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


64. Tonegutti M, Girardi V: Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions. Radiol Med; 2008 Feb;113(1):65-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions.
  • PURPOSE: We evaluated the reliability of stereotactic vacuum-assisted breast biopsies (VAB) from our personal experience.
  • Inclusion criteria were nonpalpable lesions, undetectable by ultrasound and suspected at mammography (microcalcifications, circumscribed mass, architectural distortion), for which cytology and/or core biopsy could not provide a definite diagnosis.
  • On the basis of the Breast Imaging Reporting and Data System (BI-RADS) classification, 16 cases (7%) were graded as highly suspicious for malignancy (BI-RADS 5), 81 (34%) as suspicious for malignancy (BI-RADS 4b), 97 (40%) as indeterminate (BI-RADS 4a) and 46 (19%) as probably benign (BI-RADS 3).
  • RESULTS: In 28/268 lesions (10.5%) the biopsy could not be performed (nonidentification of the lesion; inaccessibility due to location or breast size).
  • Pathology revealed 100/240 (42%) malignant or borderline lesions and 140/240 (58%) benign lesions.
  • CONCLUSIONS: In our experience, VAB showed fair reliability in the diagnosis of nonpalpable breast lesions despite a portion of failed (10.5%), nonsignificant (5%) procedures and underestimated lesions (9%).
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Stereotaxic Techniques
  • [MeSH-minor] Adult. Aged. Calcinosis / diagnostic imaging. Calcinosis / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia. Mammary Glands, Human / pathology. Mammography. Middle Aged. Neoplasm Invasiveness. Reproducibility of Results. Vacuum

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2002 Aug;224(2):548-54 [12147855.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] AJR Am J Roentgenol. 1999 May;172(5):1405-7 [10227526.001]
  • [Cites] JAMA. 1999 May 5;281(17 ):1638-41 [10235159.001]
  • [Cites] Radiology. 1998 Jul;208(1):251-60 [9646821.001]
  • [Cites] Radiology. 1997 Mar;202(3):843-7 [9051043.001]
  • [Cites] Radiology. 1997 Apr;203(1):151-7 [9122384.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jul;171(1):35-40 [9648759.001]
  • [Cites] AJR Am J Roentgenol. 1999 Mar;172(3):683-7 [10063860.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):245-51 [14716757.001]
  • [Cites] Acta Radiol. 1997 Sep;38(5):815-20 [9332236.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):53-8 [10882245.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Radiology. 2001 Feb;218(2):497-502 [11161168.001]
  • [Cites] Eur J Radiol. 2005 Aug;55(2):270-6 [16036159.001]
  • [Cites] Radiology. 1997 Aug;204(2):575-6 [9240556.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):387-91 [12846688.001]
  • [Cites] AJR Am J Roentgenol. 1992 Mar;158(3):521-6 [1310825.001]
  • [Cites] Radiographics. 1997 Sep-Oct;17(5):1233-52 [9308112.001]
  • [Cites] AJR Am J Roentgenol. 1996 Feb;166(2):341-6 [8553943.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):227-9 [10397131.001]
  • [Cites] Radiol Med. 2004 Oct;108(4):335-44 [15525887.001]
  • [Cites] Radiology. 2006 Apr;239(1):61-70 [16567483.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):173-7 [11148574.001]
  • [Cites] Radiology. 1997 Nov;205(2):423-8 [9356623.001]
  • [Cites] Am Surg. 1997 Nov;63(11):988-95 [9358788.001]
  • [Cites] Clin Radiol. 2006 Mar;61(3):276-81 [16488210.001]
  • [Cites] Radiology. 1987 Oct;165(1):99-102 [3628796.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;101(3):291-7 [16823506.001]
  • [Cites] Radiology. 1994 Nov;193(2):359-64 [7972743.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1341-6 [11044038.001]
  • [Cites] Radiology. 2001 Mar;218(3):866-72 [11230668.001]
  • [Cites] Eur Radiol. 1998;8(3):377-85 [9510569.001]
  • [Cites] Eur Radiol. 2002 Mar;12(3):638-45 [11870480.001]
  • [Cites] Pathologica. 2002 Aug;94(4):182-9 [12325416.001]
  • [Cites] Radiology. 1984 Feb;150(2):335-7 [6691085.001]
  • (PMID = 18338128.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


65. Wu J, Brinker DA, Haas M, Montgomery EA, Argani P: Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. Int J Surg Pathol; 2005 Jan;13(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy.
  • Alveolar soft part sarcoma (ASPS) is a rare neoplasm that most commonly presents in the lower extremities.
  • To our knowledge, only 1 case of ASPS arising within the breast has previously been reported.
  • The patient was a 44-year-old woman who presented with a breast mass.
  • The cells labeled strongly for the histiocytic marker CD68, suggesting a benign macrophage-rich lesion.
  • The diagnosis of ASPS was confirmed by electron microscopy, which revealed characteristic membrane-bound rhomboidal crystals, as well as by nuclear labeling for TFE3 protein by immunohistochemistry.
  • [MeSH-major] Breast Neoplasms / pathology. DNA-Binding Proteins. Deoxycytidine / analogs & derivatives. Sarcoma / secondary. Soft Tissue Neoplasms / pathology. Transcription Factors. Xanthomatosis / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Antimetabolites, Antineoplastic / therapeutic use. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Biomarkers, Tumor / analysis. Cytoplasmic Vesicles / ultrastructure. Female. Humans. Microscopy, Electron, Transmission. Treatment Outcome

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735860.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA88843
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antimetabolites, Antineoplastic; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / DNA-Binding Proteins; 0 / TFE3 protein, human; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


66. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


67. McLaughlin RA, Scolaro L, Robbins P, Hamza S, Saunders C, Sampson DD: Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer. Cancer Res; 2010 Apr 1;70(7):2579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic assessment is the gold standard technique for the identification of metastatic involvement of lymph nodes in malignant disease, but can only be performed ex vivo and often results in the unnecessary excision of healthy lymph nodes, leading to complications such as lymphedema.
  • In this morphologic study, we show the capability of OCT to image nodal microarchitecture through an assessment of fresh, unstained ex vivo lymph node samples.
  • Examples include both benign human axillary lymph nodes and nodes containing metastatic breast carcinoma.
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / ultrastructure. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrastructure. Female. Humans. Lymphatic Metastasis. Neoplasm Staging / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233873.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Burkholder HC, Witherspoon LE, Burns RP, Horn JS, Biderman MD: Breast surgery techniques: preoperative bracketing wire localization by surgeons. Am Surg; 2007 Jun;73(6):574-8; discussion 578-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast surgery techniques: preoperative bracketing wire localization by surgeons.
  • With the development of expertise in image guidance for breast surgery, many surgeons now perform preoperative wire localization themselves.
  • Use of a single wire versus multiple wires to bracket a radiographic breast abnormality has previously been described, although benefits of this technique based on clinical outcomes such as margin status, tissue volume removed, and re-excision rates have not been established.
  • This study is a retrospective analysis of wire-localized breast biopsies performed by 14 surgeons over 29 months; stereotactic and ultrasound guidance were used.
  • After controlling for tumor node metastases stage, single and multiple wire placements were compared using endpoints of margin status, need for re-excision, and total volume of tissue removed.
  • Use of more than one localizing wire was associated with greater volume of tissue removal (measured in centimeters cubed) in benign disease (46 vs 25, P < 0.001), equivalent volumes in stage 0 disease (73 vs 67), less volume in stage 1 disease (113 vs 164), and less volume in stages 2 through 4 (158 vs 207, P = 0.03).
  • Outcomes based on surgeon case volume during the study period demonstrated that low- (1-40), medium- (41-80), and high-volume (>80) surgeons did not differ in the type or stage of breast pathology treated.
  • Surgeons with high case volumes were more likely to place multiple localizing wires (P < 0.001) and were more likely to do a breast-conserving procedure if re-excision was performed (P < 0.018).
  • Surgeon experience has a positive impact on quality outcome measures such as performance of a definitive procedure at the time of initial surgery and use of breast-conserving procedures at the time of re-excision.
  • Multiple wire localization can be used to significantly reduce the volume of breast tissue removed in malignant disease without sacrificing margin status or increasing the need for future re-excision.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy / instrumentation. Stereotaxic Techniques / instrumentation
  • [MeSH-minor] Biopsy / instrumentation. Breast / pathology. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis / pathology. Mastectomy, Segmental / instrumentation. Neoplasm Staging. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Reoperation. Retrospective Studies. Surgery, Computer-Assisted / instrumentation. Treatment Outcome. Ultrasonography, Interventional / instrumentation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658094.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Cao D, Polyak K, Halushka MK, Nassar H, Kouprina N, Iacobuzio-Donahue C, Wu X, Sukumar S, Hicks J, De Marzo A, Argani P: Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res; 2008;10(5):R91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Although lobular carcinoma in situ (LCIS) has traditionally been viewed as a marker of breast cancer risk, recent clinical, pathological and genetic analyses have supported the concept that LCIS is a low risk, direct precursor of invasive lobular carcinoma.
  • By comparing the gene expression profile of LCIS to that of benign breast epithelium and stroma, we identified several genes up and down regulated in LCIS.
  • RESULTS: We identified down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 in LCIS relative to normal breast epithelium and stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):197-210 [11072784.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] JAMA. 1967 Jul 10;201(2):82-6 [6072345.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):741-51 [15696125.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] Adv Anat Pathol. 2006 Jul;13(4):157-65 [16858149.001]
  • [Cites] BMC Cancer. 2006;6:186 [16836752.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):427-37 [17325485.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):260-6 [17721269.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4606-13 [18559505.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):5-7 [18598938.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):292-6 [11274638.001]
  • [Cites] Br J Cancer. 2001 Jun 1;84(11):1488-96 [11384099.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Surg Pathol. 2001 Apr;9(2):127-31 [11484500.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):125-9 [12531579.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):208-15 [12800196.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):653-61 [12875984.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2562-72 [15197797.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer. 1974 Sep;34(3):554-63 [4853024.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1403-16 [8839545.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):41-6 [9457256.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Annu Rev Physiol. 1998;60:121-42 [9558457.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2876-80 [9661905.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4721-7 [9788628.001]
  • [Cites] Histopathology. 1999 Sep;35(3):195-200 [10469210.001]
  • [Cites] Semin Diagn Pathol. 1999 Aug;16(3):209-23 [10490198.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • (PMID = 18954444.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50 CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2614499
  •  go-up   go-down


70. Zhu Q, Hegde PU, Ricci A Jr, Kane M, Cronin EB, Ardeshirpour Y, Xu C, Aguirre A, Kurtzman SH, Deckers PJ, Tannenbaum SH: Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology; 2010 Aug;256(2):367-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis.
  • PURPOSE: To investigate the potential role of optical tomography in the near-infrared (NIR) spectrum with ultrasonographic (US) localization as a means of differentiating early-stage cancers from benign lesions of the breast.
  • From this measurement, tumor angiogenesis was assessed on the basis of calculated total hemoglobin concentration (tHb) and was correlated with core biopsy results.
  • RESULTS: There were two in situ carcinomas (Tis), 35 T1 carcinomas, 24 T2-T4 carcinomas, and 114 benign lesions.
  • The mean maximum and mean average tHb of the benign group were 55.1 micromol/L +/- 22.7 and 39.1 micromol/L +/- 14.9, respectively.
  • Both mean maximum and mean average tHb levels were significantly higher in the malignant groups than they were in the benign group (P < .001).
  • CONCLUSION: The angiogenesis (tHb) contrast imaged by using the NIR technique with US holds promise as an adjunct to mammography and US for distinguishing early-stage invasive breast cancers from benign lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2004 Jan;230(1):42-8 [14695385.001]
  • [Cites] J Pathol. 2004 Oct;204(2):140-6 [15376259.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] Arch Surg. 1996 Mar;131(3):301-8 [8611096.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Radiology. 2004 Dec;233(3):857-67 [15567802.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1152-60 [15568935.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):72-9 [15797295.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):263-70 [15799826.001]
  • [Cites] Appl Opt. 2005 Apr 10;44(11):2140-53 [15835360.001]
  • [Cites] Radiology. 2005 May;235(2):396-401 [15770039.001]
  • [Cites] Med Phys. 2005 Apr;32(4):1128-39 [15895597.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2429-49 [15901947.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2489-502 [15901950.001]
  • [Cites] Invest Radiol. 2005 Jun;40(6):328-35 [15905718.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024033 [15910106.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):934-47 [16023382.001]
  • [Cites] Acad Radiol. 2005 Aug;12(8):925-33 [16023383.001]
  • [Cites] Radiology. 2005 Oct;237(1):57-66 [16183924.001]
  • [Cites] Breast Cancer Res. 2005;7(6):279-85 [16457705.001]
  • [Cites] Radiol Med. 2006 Apr;111(3):440-8 [16683089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8828-33 [16731633.001]
  • [Cites] Technol Cancer Res Treat. 2006 Aug;5(4):365-80 [16866567.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4014-9 [17360469.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5474-9 [17875777.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):9-22 [17468951.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):539-44 [18267357.001]
  • [Cites] Acad Radiol. 2008 Jul;15(7):859-66 [18572121.001]
  • [Cites] Neoplasia. 2008 Oct;10(10):1028-40 [18813360.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044002 [19021330.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1363-80 [19197974.001]
  • [Cites] Radiology. 2009 Sep;252(3):665-72 [19567644.001]
  • [Cites] J Biomed Opt. 2009 Jul-Aug;14(4):044005 [19725717.001]
  • [Cites] Clin Radiol. 2000 Jan;55(1):40-4 [10650109.001]
  • [Cites] Radiology. 2000 Dec;217(3):841-8 [11110952.001]
  • [Cites] Ultrasound Med Biol. 2002 Jan;28(1):19-26 [11879948.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):347-54 [12082551.001]
  • [Cites] Opt Lett. 2003 Mar 1;28(5):337-9 [12659436.001]
  • [Cites] Neoplasia. 2003 Sep-Oct;5(5):379-88 [14670175.001]
  • (PMID = 20571122.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002136
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2909434
  •  go-up   go-down


71. Kuijper A, de Vos RA, Lagendijk JH, van der Wall E, van Diest PJ: Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol; 2005 May;123(5):690-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
  • We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 21; borderline, 8; malignant, 11) and 7 recurrent tumors of different grades.
  • Stromal overexpression of p16INK4A, p53, cyclin A, pRb, and p21waf1 correlated significantly with tumor grade.
  • Stromal cyclin A expression was the best separating marker between tumor grades.
  • The stromal component of mammary phyllodes tumors displays an increasing level of cell cycle deregulation with higher tumor grade; the epithelial compartment mostly remains inconspicuous.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Cycle. Cell Cycle Proteins / metabolism. Phyllodes Tumor / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis


72. Seeger H, Wallwiener D, Mueck AO: Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol; 2008 Oct;24(10):576-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
  • BACKGROUND: Epidemiological data suggest an enhanced breast cancer risk during estrogen/progestogen therapy as compared to estrogen monotherapy in postmenopausal women.
  • Estrogens are known to be mitogenic agents for benign and cancerous breast epithelial cells whereas the role of progestogens is unclear.
  • Tumor-associated macrophages play a crucial role in tumor growth and metastasis due to the synthesis of various cytokines such as tumor necrosis factor-alpha (TNF-alpha), which can stimulate the synthesis of proliferative and angiogenic factors in tumor cells.
  • METHODS: MCF-7 cells, a human estrogen- and progesterone-receptor-positive human breast cancer cell line, were used for the experiments.
  • CONCLUSION: Our results indicate that E(2) may have a stimulating effect on pre-existing tumor growth and metastasis.
  • Thus the choice of progestogen addition to estrogen therapy may be important, especially since different effects can occur in the case of pre-existing tumor cells.
  • [MeSH-major] Biomarkers / metabolism. Breast Neoplasms / pathology. Cell Proliferation. Estradiol / pharmacology. Progestins / pharmacology. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Chemokine CCL2 / analysis. Chemokine CCL2 / metabolism. Dose-Response Relationship, Drug. Female. Humans. Matrix Metalloproteinase 9 / metabolism. Medroxyprogesterone Acetate / pharmacology. Neoplasm Metastasis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012101.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Progestins; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 4TI98Z838E / Estradiol; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


73. Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, Hsieh FJ: SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J; 2010 May-Jun;16(3):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
  • The purpose of this study was to characterize the immunohistochemical distribution of secreted protein acidic and rich in cystein (SPARC) in benign and malignant breast tumors of different histologic types and define its association with the outcome of invasive ductal carcinoma (IDC) patients.
  • A total of 286 samples of benign and malignant breast lesions between 1994 and 2005 were retrieved from National Taiwan University Hospital.
  • Secreted protein acidic and rich in cystein was not expressed in benign breast phylloides and all benign breast tumors, while expressed in 17.2% of IDC, 85% of metaplastic carcinoma of the breast (MCB), and all malignant breast phylloides.
  • Individuals with positive SPARC expression had 2.34 times higher hazard of death compared with those with negative SPARC expression after adjusting for factors including positive lymph node, TNM tumor stage, estrogen receptor, and progesterone receptor.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Osteonectin / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. Proportional Hazards Models

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210803.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  •  go-up   go-down


74. Puisieux A: [Inactivation of failsafe programs by Twist oncoproteins and tumor progression]. Ann Pharm Fr; 2008 Nov-Dec;66(5-6):278-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inactivation of failsafe programs by Twist oncoproteins and tumor progression].
  • [Transliterated title] Inactivation des systèmes de sauvegarde cellulaire par les oncoprotéines Twist et progression tumorale.
  • Hence, in benign tumors, aberrant mitogenic activity is counterbalanced by the induction of these oncosuppressive pathways, leading to either apoptosis or senescence which both limit tumor outgrowth.
  • Based on our work on Twist oncoproteins, we propose a presentation of recent data on cellular mechanisms by which cancer cells override the surveillance machinery and escape senescence and apoptosis, and we will describe the biological impact of this process on tumor metastasis.
  • [MeSH-major] Neoplasm Metastasis / pathology. Neoplasm Proteins / physiology. Nuclear Proteins / physiology. Repressor Proteins / physiology. Twist Transcription Factor / physiology
  • [MeSH-minor] Animals. Apoptosis / physiology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Aging / physiology. Disease Progression. Female. Gene Amplification / physiology. Genes, myc. Humans. Neoplasm Invasiveness. Neuroblastoma / metabolism. Neuroblastoma / pathology. Proto-Oncogene Proteins c-myc / physiology. Tumor Suppressor Protein p53 / physiology. Tumor Suppressor Proteins / antagonists & inhibitors. Tumor Suppressor Proteins / physiology. ras Proteins / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061727.001).
  • [ISSN] 0003-4509
  • [Journal-full-title] Annales pharmaceutiques françaises
  • [ISO-abbreviation] Ann Pharm Fr
  • [Language] fre
  • [Publication-type] Addresses; English Abstract
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Repressor Proteins; 0 / TWIST1 protein, human; 0 / TWIST2 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Twist Transcription Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


75. Youk JH, Kim EK, Kim MJ, Oh KK: Imaging findings of chest wall lesions on breast sonography. J Ultrasound Med; 2008 Jan;27(1):125-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings of chest wall lesions on breast sonography.
  • OBJECTIVE: The purpose of this presentation is to illustrate the sonographic findings of chest wall lesions that were depicted on breast sonography.
  • METHODS: Chest wall lesions detected during breast sonography were collected and reviewed retrospectively.
  • RESULTS: The sonographic findings of normal chest walls and various pathologic chest wall lesions, including inflammatory lesions, benign neoplasms, and malignant neoplasms, are discussed.
  • CONCLUSIONS: Familiarity with normal sonographic anatomy and chest wall lesions could be helpful in differentiating a chest wall lesion from a breast lesion and in showing whether the origin of any palpable breast lump is in the breast parenchyma or the chest wall on breast sonography.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Thoracic Wall / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / ultrasonography. Neoplasm Recurrence, Local / ultrasonography. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096738.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The identification as well as the molecular characterization of breast precancerous lesions in terms of increased risk of progression and/or recurrence is becoming a critical issue today as improved non-surgical procedures are detecting cancer at an earlier stage.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • First, we identify specific protein biomarkers for benign apocrine metaplasia and thereafter we search for biomarkers that are highly overexpressed by pure invasive apocrine carcinomas.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • The latter is a benign proliferative lesion of the breast that exhibits an increase in the size of the TDLUs and characterized by retained two-cell lining, and myoepithelial (ME) and stromal hyperplasia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Fibrocystic Breast Disease / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


77. Yonemori K, Hasegawa T, Shimizu C, Shibata T, Matsumoto K, Kouno T, Ando M, Katsumata N, Fujiwara Y: Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract; 2006;202(10):705-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
  • Phyllodes tumors are rare primary tumors of the breast.
  • The study aimed at evaluating the immunohistochemical features of phyllodes tumors of the breast that may be useful for predicting the clinical outcome.
  • The study included 41 patients with phyllodes tumor (20 benign, 5 borderline, and 16 malignant).
  • [MeSH-major] Breast Neoplasms / metabolism. Ki-67 Antigen / metabolism. Phyllodes Tumor / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local. Survival Rate


78. De Vries J, Van der Steeg AF, Roukema JA: Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast. Br J Health Psychol; 2009 Feb;14(Pt 1):143-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast.
  • OBJECTIVES: The aim was to examine the role of trait anxiety and diagnosis on depressive symptoms and fatigue in women with early stage breast cancer or benign breast problems.
  • METHODS: From the 169 participating women, 81 patients had breast cancer and 88 benign breast problems.
  • Questionnaires for depressive symptoms and fatigue were completed before diagnosis (T1) and 1 (T2), 3 (T3), and 6 (T4) months after diagnosis (benign patients) or surgical treatment (breast cancer patients).
  • A trait anxiety questionnaire was only completed before diagnosis was known.
  • RESULTS: Trait anxiety, assessed before diagnosis, was the only significant predictor of depressive symptoms at T4, even when depressive symptoms at baseline was included in the analysis.
  • Demographic characteristics, diagnosis (benign or breast cancer) and adjuvant treatment (chemotherapy, radiotherapy, hormone therapy) did not play a role.
  • Patients with breast cancer or benign breast problems scoring high on trait anxiety, scored higher on depressive symptoms and fatigue than the other patients, at all time points.
  • [MeSH-major] Anxiety Disorders / epidemiology. Anxiety Disorders / psychology. Breast Neoplasms / epidemiology. Breast Neoplasms / psychology. Depressive Disorder / epidemiology. Depressive Disorder / psychology. Fatigue / epidemiology. Fatigue / psychology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Neoplasm Staging. Prospective Studies. Severity of Illness Index. Surveys and Questionnaires


79. Song J, Yang W, Shih IeM, Zhang Z, Bai J: Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochim Biophys Acta; 2006 Jan;1760(1):62-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of BCOX1, a novel gene overexpressed in breast cancer.
  • The identification of tumor-associated antigens, which are specifically expressed in cancer tissues, is of utmost important for immunotherapy of breast cancer.
  • We have combined in silico screening and experimental expression analysis to identify genes that are differentially expressed in breast carcinomas compared with their corresponding normal tissues.
  • Using these approaches, we identified a novel gene, BCOX1, with overexpression in breast carcinoma.
  • RNA in situ hybridization shows that BCOX1 mRNA signal is mainly located in the cytoplasm of breast carcinoma epithelial cells, but not in those of normal epithelial cells, stroma cells and lymphocytes.
  • Furthermore, mRNA expression of BCOX1 was moderately elevated in ductal in situ carcinoma (DCIS), peaked in invasive breast carcinoma (IBC) and metastatic breast carcinoma cells (MET) whereas absent in benign ductal epithelial cells.
  • The predicted BCOX1 open reading frame of 666 bp encodes a putative protein of 222 amino acid residues with a calculated molecular weight of 2,4920 Da and a PI of 5.86.
  • This study warrants further investigations to explore the molecular functions of BCOX1, and to determine its potential diagnostic and therapeutic applications for breast cancer.
  • [MeSH-major] Antigens, Neoplasm / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics
  • [MeSH-minor] Chromosomes, Human, Pair 17. Computational Biology. Cytoplasm / chemistry. Epithelial Cells / chemistry. Female. Gene Expression Profiling. Humans. Molecular Sequence Data. Open Reading Frames. RNA, Messenger / analysis. Tissue Distribution


80. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


81. Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R: Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer; 2006 Feb 15;106(4):732-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography.
  • METHODS: Breast Cancer Surveillance Consortium data from 1996-2001 were used to identify pathology specimens that were obtained within 1 year of screening mammograms performed on 786,846 women ages 40-89 years.
  • The pathology results were classified as invasive carcinoma, ductal carcinoma in situ (DCIS), or benign.
  • The associations between overall pathology outcomes and invasive tumor size and lymph node status were analyzed by age and mammography assessment category.
  • The 1,664,032 screening mammograms were followed by 26,748 known biopsies (1.6%) and 8815 diagnoses of breast carcinoma (0.53%).
  • Most invasive tumors measured between 0 mm and 10 mm (35%) or between 11 mm and 20 mm (36%) in greatest dimension, and 92% and 78% were lymph node-negative tumors, respectively: Biopsy results that were classified as malignant increased with age (P < 0.0001) and were most likely to follow Breast Imaging, Reporting, and Diagnosis System Category 5 and 4 assessments, respectively.
  • Ductal hyperplasia (19.6%), fibroadenoma (18.5%), and other benign findings (56.1%) were the most common benign diagnoses.
  • The prevalence of invasive carcinoma, DCIS, and benign findings presented herein establish a range of expected biopsy outcomes for women after screening mammography in the general U.S. population.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16411214.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01-CA86082; United States / NCI NIH HHS / CA / U01-CA63740; United States / NCI NIH HHS / CA / U01-CA69976; United States / NCI NIH HHS / CA / U01-CA70040; United States / NCI NIH HHS / CA / U01 CA086082; United States / NCI NIH HHS / CA / U01-CA86076; United States / NCI NIH HHS / CA / U01-CA70013; United States / NCI NIH HHS / CA / U01-CA63731
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


82. Dugina VB, Chipysheva TA, Ermilova VD, Gabbiani D, Chaponnier C, Vasil'ev IuM: [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells]. Arkh Patol; 2008 Mar-Apr;70(2):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells].
  • The distribution of beta- and gamma-cytoplasmic actins was compared in the normal cells and dysplastic malignant breast epithelial cells.
  • The authors' findings suggest that specific monoclonal antibodies to beta- and gamma-cytoplasmic actins may be used as supplementary markers that can differentiate benign and malignant breast neoplasms.
  • [MeSH-major] Actins / metabolism. Breast Neoplasms / metabolism. Fibroadenoma / metabolism. Fibrocystic Breast Disease / metabolism. Mammary Glands, Human / metabolism. Neoplasm Proteins / metabolism. Papilloma / metabolism
  • [MeSH-minor] Female. Humans. Protein Isoforms / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540438.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  •  go-up   go-down


83. Bisdas S, Baghi M, Huebner F, Mueller C, Knecht R, Vorbuchner M, Ruff J, Gstoettner W, Vogl TJ: In vivo proton MR spectroscopy of primary tumours, nodal and recurrent disease of the extracranial head and neck. Eur Radiol; 2007 Jan;17(1):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign and malignant neoplasms as well as metastatic lymph nodes of 39 patients were examined using localized single voxel magnetic resonance spectroscopy (MRS) [repetition time (TR) 1500, echo time (TE) 135) at 1.5 T.
  • The Cho/Cr ratios in all malignant neoplasms (mean: 5.2, range: 1.7-17.8) were significantly elevated relative to those in the normal muscle structures (mean: 0.9, range: 0.2-1.4), while those in the benign neoplasms were elevated (mean: 24.4, range: 1.4-59.7) with respect to those in the malignant ones.
  • The average Cho/Cr ratio in the metastatic lymph nodes was significantly higher (mean: 4.8, range: 3.3-5.6) than that for benign lymphoid hyperplasia (mean: 2.2, range: 1.0-3.0).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Magnetic Resonance Spectroscopy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(12):4402-6 [2734292.001]
  • [Cites] Magn Reson Med. 1993 Apr;29(4):436-40 [8385259.001]
  • [Cites] Breast Cancer Res. 2005;7(4):149-52 [15987466.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1696-704 [15569733.001]
  • [Cites] NMR Biomed. 1998 Nov;11(7):360-9 [9859942.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1057-72 [9194433.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1133-8 [10871028.001]
  • [Cites] Radiology. 1997 Sep;204(3):661-6 [9280241.001]
  • [Cites] Eur Radiol. 2005 Apr;15(4):645-52 [15627189.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):233-46 [15091129.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):484-90 [15037477.001]
  • [Cites] Am J Med. 1994 Apr;96(4):383-8 [8166160.001]
  • [Cites] NMR Biomed. 1998 Oct;11(6):266-72 [9802468.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):557-65 [15560713.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1381-9 [12873684.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Nov-Dec;21(10):1930-5 [11110549.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):183-93 [10669248.001]
  • [Cites] Magn Reson Med. 2001 May;45(5):765-9 [11323802.001]
  • [Cites] Invasion Metastasis. 1993;13(2):57-71 [8225853.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3030-4 [15833828.001]
  • (PMID = 16703309.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Kwon MS, Kim SJ, Lee SY, Jeong JH, Lee ES, Kang HS: Epigenetic silencing of the sulfotransferase 1A1 gene by hypermethylation in breast tissue. Oncol Rep; 2006 Jan;15(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of the sulfotransferase 1A1 gene by hypermethylation in breast tissue.
  • This study was intended to evaluate the methylation status and transcriptional activity of SULT1A1 in breast cancer tissue (n=56), benign breast tissue (n=20) and morphologically normal breast tissue (n=20), examined by bisulfite genomic sequencing and reverse transcription (RT)-PCR.
  • As a result, the methylation of the proximal promoter (P1) was identified in 64.3% of breast carcinomas, 15% of normal and 20% of benign breast tissues.
  • In terms of the distal promoter (P0), 32 of 56 cancer tissues (57.1%) were methylated, while 4 normal (20%) and 6 benign tissues (30%) were methylated.
  • Breast cancer tissue showed a higher methylation rate of SULT1A1 than normal and benign tissue at both P1 (p=0.001) and P0 (p=0.006) promoters with statistical significance.
  • Furthermore, cancer tissue showed a higher methylation density rate than normal and benign breast tissue at both P1 and P0 promoters (P1, p=0.001; P0, p=0.001).
  • Although the number of samples was relatively small, our results suggest that DNA methylation in the SULT1A1 gene appears to be present in breast tissue including cancer and methylation significantly impacts transcriptional silencing of the gene.
  • In addition, it can be suggested that progressive SULT1A1 methylation within the promoter area of the gene occurs during breast carcinogenesis.
  • [MeSH-major] Arylsulfotransferase / genetics. Breast Neoplasms / enzymology. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing
  • [MeSH-minor] CpG Islands. Epigenesis, Genetic. Female. Genes, Neoplasm / genetics. Humans. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328031.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


85. Clarke LE, Seykora JT: Primary cutaneous adenomyoepithelioma. J Cutan Pathol; 2007 Aug;34(8):654-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 83-year-old Caucasian woman presented to her dermatologist with a 5-cm subcutaneous tumor on her right thigh.
  • Incisional biopsy showed a multinodular tumor composed of variably sized glands comprised of a luminal layer of epithelial cells surrounded by one or more layers of myoepithelial cells.
  • The histopathologic features resembled those of adenomyoepithelioma, an uncommon neoplasm usually encountered within the breast.
  • Primary cutaneous adenomyoepithelioma is very rare yet shares histopathologic features with common cutaneous lesions such as spiradenomas and benign mixed tumors (chondroid syringomas).
  • Primary cutaneous adenomyoepithelioma is part of the spectrum of epithelial-myoepithelial tumors that includes benign mixed tumor, myoepithelioma and myoepithelial carcinoma.
  • This rare tumor may mimic malignant lesions including metastatic adenocarcinoma.
  • Like its breast counterpart, primary cutaneous adenomyoepithelioma should probably be regarded as a neoplasm of borderline malignant potential.
  • [MeSH-minor] Aged, 80 and over. Biopsy. Female. Humans. Thigh

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640238.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


86. Choi YD, Gong GY, Kim MJ, Lee JS, Nam JH, Juhng SW, Choi C: Clinical and cytologic features of papillary neoplasms of the breast. Acta Cytol; 2006 Jan-Feb;50(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytologic features of papillary neoplasms of the breast.
  • OBJECTIVE: To compare the cytologic features benign and malignant papillary breast lesions.
  • RESULTS: Of the features evaluated, the diameter of the mass, naked bipolar nuclei and cell balls differed significantly between benign and atypical or malignant papillary neoplasms.
  • The average diameter of a benign papillary neoplasm was 1.8 cm, and that of an atypical or malignant papillary neoplasm was 2.2 cm (p = 0.042).
  • Naked bipolar nuclei were found in 27 cases of benign papillary neoplasm (93.1%) versus 19 cases of atypical or malignant papillary neoplasm (73.1%) (p = 0.050).
  • Of 17 cases in which cell balls were absent and naked bipolar nuclei present, 13 (76.5%) were benign papillary neoplasms.
  • CONCLUSION: Most cytologic features overlapped in benign and atypical or malignant papillary neoplasms.
  • Although they were not pathognomonic, naked bipolar nuclei and cell balls were cytologic features that differed significantly between benign and atypical or malignant papillary neoplasms.
  • When papillary neoplasms of the breast are suspected in a cytologic smear, the combination of clinical examination, mammography and cytologic features should be considered to make the correct diagnosis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma, Intraductal / diagnosis
  • [MeSH-minor] Biopsy. Epithelial Cells / pathology. Epithelial Cells / ultrastructure. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514838.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Bembenek A, Fischer J, Albrecht H, Kemnitz E, Gretschel S, Schneider U, Dresel S, Schlag PM: Impact of patient- and disease-specific factors on SLNB in breast cancer patients. Are current guidelines justified? World J Surg; 2007 Feb;31(2):267-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of patient- and disease-specific factors on SLNB in breast cancer patients. Are current guidelines justified?
  • BACKGROUND: The evidence on which to base guidelines for sentinel lymph node biopsy (SLNB) in breast cancer is still limited.
  • MATERIALS AND METHODS: Prospective data acquisition from patients undergoing surgery for primary invasive breast cancer was performed.
  • RESULTS: Among 455 consecutively enrolled patients, a significant inverse association to the detection rate was found for extracapsular extension of non-SLN metastases, body mass index (BMI), number of involved lymph nodes, pT category, tumor size, and age.
  • A significant association to the false-negative rate to identify macrometastases was found for pT category, tumor size, and grading.
  • Other factors, such as prior surgery, multicentric tumor growth, or vascular invasion, showed no influence.
  • A cut-point analysis revealed that a tumor size of 2 cm separated the collective of patients with the highest significance in regard to the false-negative rate (9% vs. 25%).
  • CONCLUSION: Our results indicate that SLNB can be safely used in elderly and obese patients with multicentric tumors and those having undergone prior surgery for benign breast disease.
  • [MeSH-major] Breast Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Body Mass Index. Female. Humans. Middle Aged. Neoplasm Invasiveness. Practice Guidelines as Topic. Predictive Value of Tests. Prospective Studies. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):272-7 [11923134.001]
  • [Cites] Am Surg. 2001 Jun;67(6):522-6; discussion 527-8 [11409798.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):252-9 [15028305.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9):688-92 [11597008.001]
  • [Cites] J Am Coll Surg. 1999 Mar;188(3):248-54 [10065813.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):937-42 [15838690.001]
  • [Cites] J Clin Pathol. 2003 May;56(5):327-35 [12719450.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):451-61 [15611971.001]
  • [Cites] Breast J. 2002 Mar-Apr;8(2):88-91 [11896753.001]
  • [Cites] J Am Coll Surg. 2000 Dec;191(6):593-9 [11129806.001]
  • [Cites] Am Surg. 2005 Jan;71(1):66-70 [15757061.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2540-5 [10861431.001]
  • [Cites] Clin Nucl Med. 2005 May;30(5):317-21 [15827399.001]
  • [Cites] Eur J Surg Oncol. 1999 Feb;25(1):24-9 [10188850.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):81-9 [10862199.001]
  • [Cites] J Am Coll Surg. 2001 Mar;192(3):399-409 [11245383.001]
  • [Cites] Breast J. 2005 May-Jun;11(3):188-94 [15871704.001]
  • [Cites] J Am Coll Surg. 1998 Apr;186(4):423-7 [9544956.001]
  • [Cites] Arch Surg. 1992 Apr;127(4):392-9 [1558490.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):364-8 [15837040.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):599-609 [16670385.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2553-9 [10893286.001]
  • [Cites] J Nucl Med. 2003 Jan;44(1):7-10 [12515869.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):237-44 [12462384.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):51-9 [11141225.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):784-90 [15665628.001]
  • [Cites] Eur J Surg Oncol. 2002 Dec;28(8):821-6 [12477472.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):674-6 [15051024.001]
  • [Cites] J Am Coll Surg. 2003 Dec;197(6):896-901 [14644276.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11185-92 [16322269.001]
  • [Cites] J Am Coll Surg. 1998 Mar;186(3):275-83 [9510258.001]
  • [Cites] J Surg Oncol. 1998 Dec;69(4):212-8 [9881937.001]
  • [Cites] Ann Surg. 1998 May;227(5):645-51; discussion 651-3 [9605656.001]
  • [Cites] Br J Surg. 2001 Dec;88(12 ):1644-8 [11736980.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3345-9 [15310779.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2560-6 [10893287.001]
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):125-32 [15868440.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7703-20 [16157938.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):546-53 [12904519.001]
  • [Cites] N Engl J Med. 1998 Oct 1 ;339(14 ):941-6 [9753708.001]
  • [Cites] Breast J. 2002 Jul-Aug;8(4):192-8 [12100110.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):714-5 [11078620.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):383-8 [15668261.001]
  • [Cites] Recent Results Cancer Res. 2000;157:228-36 [10857176.001]
  • [Cites] Surgery. 2000 Aug;128(2):139-44 [10922983.001]
  • (PMID = 17180478.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ: Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev; 2007;31(2):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease.
  • BACKGROUND: A cohort study was conducted among post-menopausal women to determine whether genetic polymorphisms in selected obesity-related genes (PPARG, LPL, LEPR, PON1, PON2, TNF-alpha) were associated with the progression of benign breast disease (BBD) to breast cancer and whether the selected polymorphisms modified the association between body mass and breast cancer among women with BBD.
  • METHODS: Among participants in an ongoing cohort study, 994 Caucasian post-menopausal women had a breast biopsy for BBD.
  • Of these women, 61 subsequently developed breast cancer.
  • RESULTS: In this cohort, body mass index (BMI) was positively associated with the risk of developing breast cancer.
  • In contrast, polymorphisms in PON1 (Gln192Arg) and LEPR (IVS2+6920) were associated with a decreased risk of developing invasive breast cancer.
  • No statistically significant associations were observed for polymorphisms in PPARG, PON2, LPL, or TNF and breast cancer risk or for interactions between the polymorphisms and BMI and breast cancer risk.
  • CONCLUSIONS: The findings suggest that specific polymorphisms in the PON1 and LEPR genes may play a role in progression of BBD to breast cancer among post-menopausal Caucasian women.
  • [MeSH-major] Biomarkers, Tumor / genetics. Body Weight. Breast Diseases / genetics. Breast Neoplasms / genetics. Neoplasm Proteins / genetics. Obesity / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Aryldialkylphosphatase / genetics. Cohort Studies. Female. Genetic Predisposition to Disease. Genotype. Humans. Middle Aged. PPAR gamma / genetics. Postmenopause. Receptors, Cell Surface / genetics. Receptors, Leptin. Risk Factors. Tumor Necrosis Factor-alpha / genetics


89. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M: N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res; 2005 Apr 15;11(8):2986-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
  • PURPOSE: N(1),N(12)-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages.
  • EXPERIMENTAL DESIGN: Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected.
  • DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + I patients, whereas only 10% (P < 0.0001) and 5% (P < 0.0001) of these patients were CEA- and CA19-9-positive, respectively.
  • The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032).
  • DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3-positive, respectively.
  • CONCLUSION: The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.
  • [MeSH-major] Biomarkers, Tumor. Breast Neoplasms / diagnosis. Colorectal Neoplasms / diagnosis. Spermine / analogs & derivatives
  • [MeSH-minor] Adult. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Mucin-1 / blood. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


90. Valdes EK, Feldman SM, Krassilnik N: Neuroendocrine tumor of the breast. Am Surg; 2006 Feb;72(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumor of the breast.
  • Mammary carcinoid is an uncommon neoplasm.
  • It accounts for approximately 5 per cent of all breast carcinomas.
  • However, it is still controversial whether mammary carcinoid tumors should be considered a distinct clinical entity or be treated as a variant of conventional breast carcinoma.
  • Differentiating these lesions from benign lesions such as epithelial hyperplasia and papillomas can be challenging at times.
  • We present a case of neuroendocrine tumor of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Female. Humans


91. Akin M, Irkorucu O, Koksal H, Gonul II, Gultekin S, Kurukahvecioglu O, Anadol AZ, Tekin E: Phyllodes tumor of the breast; a case series. Bratisl Lek Listy; 2010;111(5):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast; a case series.
  • BACKGROUND: Phyllodes tumor (PT) is a rare neoplasm comprising less than 1% of all breast tumors.
  • Its clinical spectrum ranges from a benign and locally recurrent form of behavior to malignant and metastatic forms.
  • All cases were histologically examined by an experienced breast pathologist, and tumors were classified as benign, borderline malignant or malignant according to standard histological criteria.
  • RESULTS: The median age at diagnosis was 45.5 years (range: 21-69 years).
  • Seven (70%) of 10 tumors were benign and 3 (30%) were malignant.
  • The median tumor size was 29 mm (range: 12-80 mm).
  • CONCLUSION: PT is a rare neoplasm of the breast.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568416.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


92. Nguyen QH, Szeto E, Mansberg R, Mansberg V: Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies. Clin Nucl Med; 2005 Apr;30(4):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old woman was referred for a bone scan to assess back pain on a background of breast cancer, melanoma, and rheumatic heart disease.
  • The scan appearance was suspicious for a localized soft tissue neoplasm.
  • Because FDG is not tumor-specific, accumulation in benign lesions may give rise to false-positive results despite a high pretest probability for malignancy.
  • [MeSH-minor] Aged. Back Pain / diagnosis. Back Pain / etiology. Breast Neoplasms / complications. Breast Neoplasms / radionuclide imaging. Diagnosis, Differential. Female. Gamma Cameras. Humans. Melanoma / complications. Melanoma / radionuclide imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764879.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


93. Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG: Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol; 2008 Apr;172(4):893-904
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
  • The cysteine-rich protein CCN6 [or Wnt-1-induced signaling protein 3 (WISP3)] exerts tumor-suppressive effects in aggressive inflammatory breast cancer.
  • Here, we show that reduction of CCN6 expression occurs in 60% of invasive breast carcinomas and is associated with axillary lymph node metastases.
  • In vitro, RNA interference knockdown of CCN6 in two benign human mammary epithelial cell lines (HME and MCF10A) decreased expression of E-cadherin protein and mRNA and reduced activity of the E-cadherin promoter; this reduction was dependent on intact E-box elements.
  • These data show, for the first time, that CCN6 expression is reduced or lost in a substantial number of invasive breast carcinomas and that CCN6 modulates transcriptional repressors of E-cadherin.
  • Together, our results lead to a new hypothesis that Snail and ZEB1 are downstream of CCN6 and play a critical role in CCN6-mediated regulation of E-cadherin in breast cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Biotechniques. 2000 Jul;29(1):78-81 [10907080.001]
  • [Cites] Mol Pathol. 2001 Apr;54(2):57-79 [11322167.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):849-59 [11891184.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3172-80 [12082632.001]
  • [Cites] Mol Pathol. 2002 Aug;55(4):250-61 [12147716.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):373-9 [12191636.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Mol Pathol. 2003 Apr;56(2):127-8 [12665631.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1445-8 [12670887.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24200-8 [12695522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R217-22 [14580257.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R110-5 [14696649.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):179-85 [15140407.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):189-90 [8459046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14717-22 [9843955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):869-74 [9927660.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):44-57 [10094812.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2511-9 [10499627.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):29-33 [15631989.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8229-37 [15611078.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11740-8 [15647282.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2375-85 [15674322.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3179-84 [15833848.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1418-23 [15941950.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4349-61 [15824736.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(2):101-10 [16187229.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1080-9 [16457688.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1398-406 [17072303.001]
  • [Cites] FEBS Lett. 2007 Apr 17;581(8):1617-24 [17391671.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • (PMID = 18321996.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA 090876; United States / NCI NIH HHS / CA / R01 CA 66712; United States / NCI NIH HHS / CA / R01 CA 107469; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / K08 CA090876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP3 protein, human; 0 / ZEB1 protein, human; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2276413
  •  go-up   go-down


94. Owens CL, Basaria S, Nicol TL: Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report. Diagn Cytopathol; 2005 Aug;33(2):110-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report.
  • We discuss a case of a 64-yr-old female with a history of breast carcinoma, who presented with pain and swelling in her neck 5 yrs after being diagnosed with breast cancer.
  • A fine-needle aspiration (FNA) of the larger thyroid nodule showed malignant epithelial cells with features consistent with breast carcinoma in a background of benign thyroid epithelial cells and colloid.
  • The case was signed out as metastatic breast carcinoma.
  • Subsequent FNA and biopsy of her right shoulder lesion also revealed metastatic breast carcinoma with similar morphology to the material in the thyroid FNA.
  • [MeSH-major] Carcinoma, Ductal, Breast. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Breast Neoplasms / complications. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007653.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Ceçener G, Egeli U, Tunca B, Taşdelen I, Tolunay S, Bilgel N: Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. Tumori; 2007 Nov-Dec;93(6):597-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of novel sequence alterations in the FHIT gene on formation of breast cancer.
  • AIMS AND BACKGROUND: The character, role and impact of FHIT gene alterations, for which recent studies have shown that the gene has a role in the early stage of carcinogenesis in breast cancer, are still unclear.
  • Thus, the current study evaluated FHIT gene mutations from breast tissue of women with malignant and benign breast disease and to elucidate the frequency and type of mutations in this gene.
  • PATIENTS AND METHODS: Mutations in exons 5-9 of the FHIT gene were screened using the intronic primer pairs in 83 breast (67 malignant and 16 benign) tissue samples by single-strand conformational polymorphism and sequencing analysis.
  • RESULTS: FHIT mutations were detected in 13 of the 67 malignant cases (19.4%) and 2 of the 16 benign cases (12.5%).
  • CONCLUSIONS: Our data contribute significantly to that currently known about the presence of FHIT gene mutations on the formation of breast cancer.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Mutation. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Alanine. Carcinoma / genetics. Female. Fibroadenoma / genetics. Frameshift Mutation. Glutamine. Humans. Hyperplasia / genetics. Lymphatic Metastasis. Middle Aged. Phenylalanine. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Threonine

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. L-Threonine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338496.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 0RH81L854J / Glutamine; 2ZD004190S / Threonine; 47E5O17Y3R / Phenylalanine; EC 3.6.- / Acid Anhydride Hydrolases; OF5P57N2ZX / Alanine
  •  go-up   go-down


96. Lincoln DT, Singal PK, Al-Banaw A: Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Anticancer Res; 2007 Nov-Dec;27(6B):4201-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 64 benign and malignant vascular tumours were obtained from different human organ sites, including the chest wall, skin, axillary contents, duodenum, female breast, abdomen, stomach, colon, lymph node, bladder, body flank and neck regions.
  • The presence of GHR in endothelial cells of vascular neoplasm indicates that they are target cells and GH is of importance in the proliferation of vascular tumour angiogenesis.
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Binding Sites. Cell Growth Processes / physiology. Female. Hemangioma / blood supply. Hemangioma / metabolism. Hemangioma / pathology. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Rabbits. Rats

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2008 Mar-Apr;28(2b):1439
  • (PMID = 18225592.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Receptors, Somatotropin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


97. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, some studies have suggested that SIRT1 could be over-expressed in breast, prostate and colon cancers and up-regulated SIRT1 inactivates p53 by deacetylation.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


98. Zeng Y, Yang WT, Zhang GH, Zhu XZ: [Study of HOXA5 gene expression in breast carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Sep;34(9):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of HOXA5 gene expression in breast carcinoma].
  • OBJECTIVE: To study mRNA and protein expression of HOXA5 gene in breast carcinoma, to correlate the expression of HOXA5 gene with clinicopathologic parameters and to explore the possible role of HOXA5 gene in carcinogenesis, progression and metastasis of breast carcinoma.
  • METHODS: TaqMan real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was applied on 60 cases of primary breast carcinoma and 24 cases of benign mammary lesions in order to detect mRNA expression of HOXA5 gene.
  • Statistical analysis was carried out to analyze the correlation between HOXA5 gene expression and various clinical parameters in these breast cancer patients. RESULTS:.
  • (1) The relative expression level of HOXA5 mRNA ranged from 0.73 to 193.07 (average = 20.85) in primary breast carcinoma, in contrast to 5.42 to 81.91 (average = 30.94) in benign mammary lesions.
  • Compared with benign mammary lesions, a significant reduction in expression of HOXA5 mRNA was noted in primary breast carcinoma (P < 0.01). (2) There was a decreased or completely diminished HOXA5 protein expression in breast carcinoma. (3) HOXA5 mRNA expression was significantly lower in lymph node-positive cases, when compared with that in lymph node-negative cases (P < 0.05).
  • On the other hand, moderately or strongly positive HOXA5 staining was noted in lymph node-negative cases. (4) Neither mRNA nor protein expression of HOXA5 gene correlated with clinicopathologic parameters such as age of patients, size of tumor, clinical stage, pathologic subtype or histologic grade (P > 0.05).
  • CONCLUSIONS: Disordered expression of HOXA5 gene may play a role in the carcinogenesis of breast cancer.
  • Reduced expression of HOXA5 gene may be related to the metastatic potential of breast carcinoma cells.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Homeodomain Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast / metabolism. Breast / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468307.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HOXA5 protein, human; 0 / Homeodomain Proteins; 0 / RNA, Messenger
  •  go-up   go-down


99. Mendrinos S, Nolen JD, Styblo T, Carlson G, Pohl J, Lewis M, Ritchie J: Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer; 2005 Jun 25;105(3):178-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry.
  • BACKGROUND: Early detection of breast carcinoma enhances the chances for patient survival.
  • The authors' work focused on an innovative technique that couples breast ductal lavage (DL) with surface-enhanced laser desorption and ionization-time of flight mass spectrometry (SELDI-TOF MS) to yield a highly sensitive and specific method of breast carcinoma detection.
  • METHODS: The study group included 16 women who had unilateral, biopsy-proven breast carcinoma.
  • Studying paired DL specimens from each woman (the breast with and the breast without carcinoma), a cytologic investigation was performed on the cells present in the DL samples, and the protein content of the DL fluid was analyzed with the SELDI-TOF MS technique using the strong anionic exchange chip surface.
  • RESULTS: Only 5 of 16 DL specimens (31%) from breasts with biopsy-proven carcinoma contained malignant cells, whereas the remaining samples contained only histiocytes and clusters of benign ductal epithelium.
  • In contrast, 12 of 16 DL specimens (75%) from breasts that contained carcinoma had a different protein peak pattern compared with the paired DL specimen from the same patient's contralateral, uninvolved breast.
  • CONCLUSIONS: The combination of breast DL with SELDI-TOF MS offers a unique and powerful technique for the detection and monitoring of breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Neoplasm Proteins / analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] BRCA1 Protein / analysis. BRCA2 Protein / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Case-Control Studies. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nipples / cytology. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822128.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


100. Dhingra KK, Mandal S, Roy S, Khurana N: Malignant peripheral nerve sheath tumor of the breast: case report. World J Surg Oncol; 2007;5:142
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the breast: case report.
  • BACKGROUND: Malignant peripheral nerve sheath tumor is a rare soft tissue sarcoma of ectomesenchymal origin.
  • It is the malignant counterpart of benign soft tissue tumors like neurofibromas and schwannomas and may often follow them.
  • Breast is an extremely rare location of this lesion and presentation as a breast lump in the absence of pain or previous benign neural tumor is even rarer.
  • CASE PRESENTATION: A 38-year-old female presented with complaints of painless, hard breast lump for three months which was clinically suspected to be a ductal carcinoma with inconclusive fine needle aspiration cytology.
  • Histopathology revealed a malignant spindle cell tumor which was confirmed to be malignant peripheral nerve sheath tumor on the basis of immunopositivity for vimentin, neurone specific enolase and S-100.
  • The differential diagnosis of malignant peripheral nerve sheath tumor should be considered by the clinician as well as the pathologists in the work-up of a breast neoplasm as treatment and prognosis of this rare malignancy is different.
  • [MeSH-major] Breast Neoplasms / pathology. Nerve Sheath Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Vimentin / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orv Hetil. 1998 Jan 18;139(3):137-9 [9467297.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1049-57 [6432304.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):155-60 [2447857.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):273-5 [7630177.001]
  • [Cites] J Med Assoc Thai. 2006 Mar;89(3):377-9 [16696423.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):332 [12846874.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1998 Jun;27(4):441-4 [9690165.001]
  • [Cites] Langenbecks Arch Chir. 1995;380(6):350-3 [8559005.001]
  • (PMID = 18154670.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2246134
  •  go-up   go-down






Advertisement